

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2007 (02.08.2007)

PCT

(10) International Publication Number
WO 2007/085357 A1

(51) International Patent Classification:

C07D 233/34 (2006.01) A61K 31/41 (2006.01)
C07D 235/02 (2006.01) A61P 29/00 (2006.01)
C07D 235/26 (2006.01) A61P 25/00 (2006.01)
C07D 401/06 (2006.01)

(21) International Application Number:

PCT/EP2007/000303

(22) International Filing Date: 15 January 2007 (15.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/762,887 30 January 2006 (30.01.2006) US

(71) Applicant (for all designated States except US): **EURO-CELTIQUE S.A.** [LU/LU]; 122. boulevard de la Pétrusse, L-2330 Luxembourg (LU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **ZHOU, Xiaoming** [US/US]; 22 Dogwood Drive, Plainsboro, NJ 08523 (US).

(74) Agent: **MAIWALD, Walter**; Maiwald Patentanwalts GmbH, Elisenhof, Elisenstrasse 3, 80335 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS



(I)

(57) Abstract: The invention relates to cycloourea compounds of Formula I; or a pharmaceutically acceptable salt or solvate thereof, wherein R¹-R³ and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

WO 2007/085357 A1

CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

Background of the Invention

5 Field of the Invention

[0001] This invention is in the field of medicinal chemistry. The invention relates to novel cyclourea compounds and the use of these compounds as blockers of calcium (Ca^{2+}) channels.

Background Art

- 10 **[0002]** Calcium ions play fundamental roles in the regulation of many cellular processes. It is therefore essential that their intracellular levels be maintained under strict, yet dynamic control (Davila, H. M., *Annals of the New York Academy of Sciences*, pp. 102-117 (1999)). Voltage-gated calcium channels (VGCC) serve as one of the important mechanisms for fast calcium influx into the cell. Calcium
- 15 channels are hetero-oligomeric proteins consisting of a pore-forming subunit ($\alpha 1$), which is able to form functional channels on its own in heterologous expression systems, and a set of auxiliary or regulatory subunits. Calcium channels have been classified based on their pharmacological and/or electrophysiological properties. The classification of voltage-gated calcium channels divides them into three groups:
- 20 (i) high voltage-activated (HVA) channels, which include L-, N-, P-, and Q-types; (ii) intermediate (IVA) voltage-activated R-type channels; and (iii) low voltage-activated (LVA) T-type channels (Davila, *supra*). Voltage-gated calcium channels (VGCC) are also known as voltage-dependent calcium channels (VDCC) or voltage-sensitive calcium channels (VSCC).
- 25 **[0003]** Voltage-sensitive calcium channels (VSCC) regulate intracellular calcium concentration, which affects various important neuronal functions such as cellular excitability, neurotransmitter release, hormone secretion, intracellular metabolism, neurosecretory activity and gene expression (Hu *et al.*, *Bioorganic & Medicinal Chemistry* 8:1203-1212 (2000)). N-type channels are found mainly in central and
- 30 peripheral neurons, being primarily located on presynaptic nerve terminals. These channels regulate the calcium flux required for depolarization-evoked release of a

- 2 -

transmitter from synaptic endings. The transmission of pain signals from the periphery to the central nervous system (CNS) is mediated by N-type calcium channels located in the spinal cord (Song *et al.*, *J. Med. Chem.* 43:3474-3477 (2000)).

5 [0004] The six types of calcium channels (*i.e.*, L, N, P, Q, R, and T) are expressed throughout the nervous system (Wallace, M. S., *The Clinical Journal of Pain* 16:580-585 (2000)). Voltage-sensitive calcium channels of the N-type exist in the superficial laminae of the dorsal horn and are thought to modulate nociceptive processing by a central mechanism. Blockade of the N-type calcium channel in the
10 superficial dorsal horn modulates membrane excitability and inhibits neurotransmitter release, resulting in pain relief. Wallace (*supra*) suggests that based on animal models, N-type calcium channel antagonists have a greater analgesic potency than sodium channel antagonists.

[0005] N-type calcium channel blockers have usefulness for neuroprotection and analgesia. Ziconotide, which is a selective N-type calcium channel blocker, has been
15 found to have analgesic activity in animal models and neuroprotective activity in focal and global ischemia models (Song *et al.*, *supra*). Examples of known calcium channel blockers include flunarizine, fluspirilene, cilnipide, PD 157767, SB-201823, SB-206284, NNC09-0026, and PD 151307 (Hu *et al.*, *supra*).

20 [0006] Blockade of N-type channels can prevent and/or attenuate subjective pain as well as primary and/or secondary hyperalgesia and allodynia in a variety of experimental and clinical conditions (Vanegas, H. *et al.*, *Pain* 85:9-18 (2000)). N-type voltage-gated calcium channels (VGCC) play a major role in the release of synaptic mediators such as glutamate, acetylcholine, dopamine, norepinephrine,
25 gamma-aminobutyric acid (GABA) and calcitonin gene-related peptide (CGRP).

[0007] Inhibition of voltage-gated L-type calcium channels has been shown to be beneficial for neuroprotection (Song *et al.*, *supra*). However, inhibition of cardiac L-type calcium channels can lead to hypotension. It is believed that a rapid and profound lowering of arterial pressure tends to counteract the neuroprotective effects
30 of L-type calcium channel blockers. A need exists for antagonists that are selective

for N-type calcium channels over L-type calcium channels to avoid potential hypotensive effects.

[0008] U.S. Patent No. 3,184,460 to Akkerman *et al.* describes 1-(alkoxyphenylalkyl)-2-imidazolidinones that act on the central nervous system.

5 [0009] Matoba *et al.* (*Chem. Pharm. Bull.* 28(6):1810-1813 (1980)) describe 1-[2-(3,4-dimethoxyphenyl)ethyl]imidazolidin-2-one, 1,3-bis[2-(3,4-dimethoxyphenyl)ethyl]imidazolidin-2-one, 1-(2-phenylethyl)imidazolidin-2-one, and 1,3-bis(2-phenylethyl)imidazolidin-2-one as intermediates.

[0010] U.S. Patent No. 6,403,805 to Freyne *et al.* describes 1,3-dihydro-1-10 (phenylalkyl)-2H-imidazol-2-one derivatives having phosphodiesterase IV (PDE IV) and cytokine inhibiting activity.

[0011] U.S. Patent Application Publication No. 2003/0069249 by Sun *et al.* describes 1,3-dihydro-2H-benzimidazol-2-one derivatives that exhibit affinity to the ORL1 receptor.

15 [0012] Wang *et al.* (*Journal of Combinatorial Chemistry* 6:899-902 (2004)) describe a solid phase synthesis of substituted benzimidazolones.

Brief Summary of the Invention

[0013] The present invention is related to the use of compounds represented by Formula I, below, as blockers of calcium (Ca^{2+}) channels. Certain compounds of 20 Formula I show selectivity as N-type calcium channel blockers.

[0014] The invention is also related to treating, preventing or ameliorating a disorder responsive to the blockade of calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I as described herein. Specifically, the invention is related to treating, 25 preventing or ameliorating a disorder responsive to the blockade of N-type calcium channels in a mammal suffering from excess activity of said channels by administering an effective amount of a compound of Formula I as described herein.

- 4 -

[0015] A number of compounds useful in the present invention have not been heretofore reported. Thus, one aspect of the present invention is directed to novel compounds of Formula I.

[0016] Another aspect of the present invention is directed to the use of the novel
5 compounds of Formula I as blockers of N-type calcium channels.

[0017] A further aspect of the present invention is to provide a method for treating, preventing or ameliorating stroke, head trauma, epilepsy, pain (e.g., acute pain or chronic pain, which includes, but is not limited to, neuropathic pain and inflammatory pain), migraine, a mood disorder, schizophrenia, a neurodegenerative
10 disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia, by administering an effective amount of a compound of Formula I to a mammal in need of such treatment, prevention or amelioration.

[0018] A further aspect of the present invention is to provide a pharmaceutical
15 composition useful for treating, preventing or ameliorating a disorder responsive to the blockade of calcium ion channels, especially N-type calcium ion channels, said pharmaceutical composition containing an effective amount of a compound of Formula I in a mixture with one or more pharmaceutically acceptable carriers.

[0019] Also, an aspect of the present invention is to provide a method of modulating
20 calcium channels, especially N-type calcium channels, in a mammal, wherein said method comprises administering to the mammal an effective amount of at least one compound of Formula I.

[0020] A further aspect of the present invention is to provide ^3H or ^{14}C radiolabeled
25 compounds of Formula I and their use as radioligands for their binding site on the calcium channel.

[0021] A further aspect of the invention is to provide a method for screening a candidate compound for the ability to bind to a receptor using a ^3H or ^{14}C radiolabeled compound of Formula I. This method comprises a) introducing a fixed concentration of the radiolabeled compound to the receptor to form a mixture; b)

titrating the mixture with a candidate compound; and c) determining the binding of the candidate compound.

[0022] A further aspect of the invention is to provide the use of a compound of Formula I for the manufacture of a medicament for treating, preventing or ameliorating stroke, head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia in a mammal. In a preferred embodiment, the invention provides the use of a compound of Formula I for the manufacture of a medicament for treating, preventing or ameliorating acute pain, chronic pain, or surgical pain.

[0023] Additional embodiments and advantages of the invention will be set forth in part in the description that follows, and will flow from the description, or may be learned by practice of the invention. The embodiments and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.


[0024] It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

Detailed Description of the Invention

[0025] One aspect of the present invention is based on the discovery that compounds of Formula I act as blockers of Ca^{2+} channels. In view of this discovery, compounds of Formula I are seen as useful for treating disorders responsive to the blockade of calcium ion channels. In one aspect, it has been found that certain compounds of Formula I selectively block N-type calcium ion channels and, thus, are useful for treating disorders responsive to the selective blockade of N-type calcium ion channels.


[0026] The compounds useful in this aspect of the invention are compounds represented by Formula I:

- 6 -




or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:

[0027] Z is selected from the group consisting of Z¹ and Z², wherein



and




5 **[0028]** R¹ and R² are both hydrogen or R¹ and R², together with the carbon atoms to which they are attached, form a fused cyclopropyl ring or a fused phenyl ring;

[0029] R³ is selected from the group consisting of



- (i) hydrogen;
- (ii) alkyl;
- (iii) C₃₋₆ cycloalkyl;
- (iv) $-(\text{CH}_2)_p-\text{Y}$;
- (v)

10



(vi)

- 7 -



[0030] R⁴, R⁵, R⁶, and R⁷ are each independently selected from the group consisting
 5 of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl,
 cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

[0031] R⁸ is selected from the group consisting of

phenyl optionally substituted with one, two or three substituents
 independently selected from the group consisting of alkyl, alkoxy, halogen,
 10 haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl,
 alkylamino, and dialkylamino;

pyridyl optionally substituted with one or two substituents
 independently selected from the group consisting of alkyl, halogen,
 haloalkyl, haloalkoxy, and alkoxy;

15 thiazolyl optionally substituted with one or two substituents
 independently selected from the group consisting of alkyl, alkoxy,
 halogen, and haloalkyl;

[0032] R⁹ and R¹⁰ are each independently selected from the group consisting of
 hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and
 20 hydroxyalkyl;

[0033] R¹¹ and R¹² are each independently selected from the group consisting of
 hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and
 hydroxyalkyl;

[0034] Y is a 3-7 membered saturated heterocyclic ring optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

[0035] m is 0, 1, 2, 3, 4, or 5;

5 [0036] n is 0, 1, or 2;

[0037] p is 0, 1, 2, 3, or 4;

[0038] q and s are independently 0, 1, 2, 3, 4, or 5;

[0039] r is 0 or 1;

[0040] t is 0, 1, 2, 3, or 4; and

10 [0041] u is 0, 1, 2, 3, or 4.

[0042] The groups R^4 - R^7 and R^9 - R^{12} , when themselves not equal to H, each take place of a hydrogen atom that would otherwise be present in any position on the aryl or heteroaryl ring to which the R group is attached. Similarly, the optional substituents attached to the phenyl, pyridyl and thiazolyl rings as defined for R^8 each take the place of a hydrogen atom that would otherwise be present in any position on the aryl or heteroaryl rings.


[0043] One group of compounds useful in this aspect of the present invention are compounds of Formula I where R^1 - R^{12} , Z, Y, m, n, p, q, r, s, t, and u are as described above, with the provisos that

20 1) when R^1 and R^2 are both hydrogen, Z is Z^2 , and R^3 is (i) or (v), where r is 0 and R^9 and R^{10} are each independently hydrogen or alkoxy, then R^8 is not phenyl or 3,4-dimethoxyphenyl; or

2) when R^1 and R^2 together form a fused phenyl ring, Z is Z^2 , and R^8 is an unsubstituted phenyl group, then R^3 is not alkyl.

25 [0044] In one embodiment, compounds useful in the present invention are compounds represented by Formula II:


- 9 -



II

or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R³ and Z are as defined above for Formula I.


[0045] In a further embodiment, compounds useful in the present invention are
5 compounds represented by Formula III:



III

or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R³ and Z are as defined above for Formula I.

10 [0046] In a further embodiment, compounds useful in the present invention are compounds represented by Formula IV:



IV

- 10 -

or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R^3 and Z are as defined above for Formula I.

[0047] In one embodiment, compounds useful in the present invention are compounds of Formulae I-IV, wherein Z is Z^1 .


5 [0048] In another embodiment, compounds useful in the present invention are compounds of Formulae I-IV, wherein Z is Z^2 .

[0049] A group of compounds useful in the present invention includes compounds of Formula I where R^3 is selected from the group consisting of (i) hydrogen, (ii) alkyl, and (iii) C_{3-6} cycloalkyl; preferably selected from the group consisting of hydrogen, 10 C_{1-4} alkyl and C_{3-6} cycloalkyl; more preferably selected from the group consisting of C_{1-4} alkyl and C_{3-6} cycloalkyl; and more preferably selected from the group consisting of methyl, ethyl, propyl, iso-propyl, butyl, tert-butyl, cyclopropyl, cyclobutyl, and cyclopentyl. Advantageously, R^3 is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, tert-butyl, and cyclopropyl.

15 [0050] Another group of compounds useful in the present invention includes compounds of Formula I where R^3 is (iv) $-(CH_2)_p-Y$, wherein Y is a 3-7 membered saturated heterocyclic ring optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl and p is 0, 1, 2, 3, or 4. 20 Preferably, Y is a 3-6 membered saturated heterocyclic ring consisting of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, wherein the heterocyclic ring is optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl; preferably independently 25 selected from the group consisting of C_{1-4} alkyl, C_{1-4} alkoxy, halogen, halo(C_{1-3})alkyl, halo(C_{1-3})alkoxy, cyano, hydroxy, and hydroxy(C_{1-4})alkyl; and more preferably selected from the group consisting of hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, trifluoromethyl, trifluoroethyl, trifluoromethoxy, cyano, hydroxy, and hydroxymethyl. Useful compounds include those where the saturated 30 heterocyclic ring is unsubstituted.

- 11 -


[0051] Advantageously, Y is a saturated heterocyclic ring having the formula



wherein R¹³ and R¹⁴ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl, and w is 0, 1, 2, or 3. Preferably, R¹³ and R¹⁴ are each independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, cyano, hydroxy, and hydroxy(C₁₋₄)alkyl; and more preferably hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, trifluoromethyl, trifluoroethyl, trifluoromethoxy, cyano, hydroxy, and hydroxymethyl.

Advantageously, R¹³ and R¹⁴ are both hydrogen. Preferably, w is 2 or 3. Useful compounds of of Formula I include those where Y is N-pyrrolidinyl or N-piperidinyl. Preferably, p is 0, 1, 2, or 3.

[0052] Another group of compounds useful in the present invention includes compounds of Formula I where R³ is (v)




wherein R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl, r is 0 or 1, and q and s are each independently 0, 1, 2, 3, 4, or 5. Preferably, R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, cyano, hydroxy, and hydroxy(C₁₋₄)alkyl; and more preferably each independently selected from the group consisting of hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, trifluoromethyl, trifluoroethyl, trifluoromethoxy, cyano, hydroxy, and hydroxymethyl. Useful compounds include those where R⁹ and R¹⁰ are both

- 12 -


hydrogen. A useful group of compounds includes those where q and r are both 0 and s is 0, 1, 2, 3, or 4; and preferably s is 0, 1, 2, or 3. Another useful group of compounds includes those where q is 1 or 2, r is 1, and s is 0, 1, 2, or 3; and preferably s is 0, 1 or 2.

- 5 [0053] Another group of compounds useful in the present invention includes compounds of Formula I where R³ is (vi)



- wherein R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl, and t is 0, 1, 2, 3, or 4. Preferably, t is 0, 1, or 2.

- [0054] Another group of compounds useful in the present invention includes compounds of Formula I where R³ is (vii)



- wherein R¹¹ and R¹² are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl, and u is 0, 1, 2, 3 or 4. Preferably, R¹¹ and R¹² are each independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, cyano, hydroxy, and hydroxy(C₁₋₄)alkyl; and more preferably each is independently selected from the group consisting of hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, trifluoromethyl, trifluoroethyl, trifluoromethoxy, cyano, hydroxy, and hydroxymethyl. Useful compounds include those where R¹¹ and R¹² are independently selected from the group consisting of hydrogen, alkyl, and halogen. Advantageously, R¹¹ and R¹² are both hydrogen. Preferably, u is 0, 1, 2, or 3, and more preferably 0, 1, or 2. The -(CH₂)_u- group is attached to the 2-, 3-, or 4-position of the pyridyl ring.


- 13 -

[0055] Preferably, R⁴, R⁵, R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, cyano, amino, alkylamino, and dialkylamino. More preferably, R⁴, R⁵, R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, halo(C₁₋₆)alkyl, halo(C₁₋₆)alkoxy, hydroxy, cyano, amino, (C₁₋₆)alkylamino and di(C₁₋₆) alkylamino; and more preferably independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, hydroxy, cyano, amino, and di(C₁₋₃)alkylamino. Advantageously, R⁴, R⁵, R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, halogen (especially fluorine), trifluoromethyl, trifluoromethoxy, hydroxy, cyano, and amino.

[0056] Useful compounds include those where R⁴ and R⁶ are both hydrogen and R⁵ and R⁷ are as defined above. Further useful compounds include those where R⁴ and R⁶ are both hydrogen and R⁵ and R⁷ are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, halogen, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, cyano, amino, and dimethylamino. Advantageously, R⁴ and R⁶ are both hydrogen and R⁵ and R⁷ are both fluorine. Preferably, either or both R⁵ and R⁷ are at the para-position of the respective phenyl rings.

20


[0057] Compounds useful in the present invention are represented by Formula V:



or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R³-R⁷ and
5 m are as defined above for Formula I. In Formula V, preferred values for R³-R⁷ and
m are those described above for Formula I.

[0058] In one embodiment, compounds useful in the present invention are
compounds represented by Formula VI:



- 15 -



VI

or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R^3 - R^7 and m are as defined above for Formula I. Preferred values for R^3 - R^7 and m are those described above for Formula I. Useful compounds of Formula VI include those


5 where R^3 is (vi) or (vii), *i.e.*,



where t , u , and R^9 - R^{12} are as defined above.

10 [0059] In another embodiment, compounds useful in the present invention are represented by Formula VII:


- 16 -



VII


or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R^3 - R^7 and m are as defined above for Formula I. Preferred values for R^3 - R^7 and m are those described above for Formula I. Useful compounds of Formula VII include those

5 where R^3 is (iv), *i.e.*, $-(CH_2)_p$ -Y, where Y is



, where R^{13} , R^{14} , and w are as defined above.

Further useful compounds of Formula VII include those where R^3 is (vii)



where u , R^{11} , and R^{12} are as defined above.

10 [0060] In one embodiment, compounds useful in the present invention are compounds of any one of Formula II-IV, where Z is Z^2 , $-(CH_2)_n$ - R^8 , wherein R^8 and n are as defined above. R^3 is as defined above.

[0061] Useful compounds include those where R⁸ is phenyl optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino; preferably independently selected
5 from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, amino, alkylamino, and dialkylamino; and more preferably independently selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, halogen, halo(C₁₋₃)alkyl, halo(C₁₋₃)alkoxy, amino, C₁₋₃ alkylamino, and di(C₁₋₃)alkylamino. Advantageously, R⁸ is phenyl optionally substituted with one, two or three substituents independently
10 selected from the group consisting of methyl, ethyl, propyl, iso-propyl, methoxy, ethoxy, halogen (especially fluorine), trifluoromethyl, trifluoromethoxy, and dimethylamino. Useful compounds include those where R⁸ is phenyl substituted with one, two or three substituents as defined above.

[0062] Useful compounds include those where R⁸ is pyridyl, especially pyrid-2-yl,
15 pyrid-3-yl, or pyrid-4-yl, optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, and alkoxy; preferably independently selected from the group consisting of alkyl, alkoxy, and haloalkoxy; and more preferably selected from the group consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy, and halo(C₁₋₃)alkoxy. Advantageously, R⁸ is
20 pyridyl optionally substituted with one or two substituents independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy. Useful compounds include those where R⁸ is pyridyl substituted with one or two substituents as defined above.

[0063] Useful compounds include those where R⁸ is thiazolyl, especially thiazol-4-yl
25 or thiazol-5-yl, optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, and haloalkyl; preferably independently selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, and halo(C₁₋₃)alkyl; and more preferably independently selected from the group consisting of methyl, ethyl, iso-propyl, methoxy, ethoxy, halogen
30 (especially fluorine), and trifluoromethyl.

[0064] Preferably, n is 0 or 1.

[0065] Exemplary compounds that may be employed in the methods of the present invention include:

- 1-(3,3-diphenylpropyl)-3-phenylimidazolidin-2-one;
- 5 1-[4,4-bis(4-fluorophenyl)butyl]-3-phenylimidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-(3-phenylprop-2-enyl)imidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-3-ylmethyl)imidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-4-ylmethyl)imidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-2-ylmethyl)imidazolidin-2-one;
- 10 1-[4,4-bis(4-fluorophenyl)butyl]-3-methylimidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-cyclopropylimidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(pyrrolidin-1-yl)ethyl]imidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(piperidin-1-yl)ethyl]imidazolidin-2-
- 15 one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-imidazolidin-2-one;

and pharmaceutically acceptable salts, prodrugs and solvates thereof.

[0066] Other exemplary compounds useful in the methods of the present invention include:

- 20 2-[4,4-bis(4-fluorophenyl)butyl]-4-methyl-2,4-diazabicyclo[3.1.0]hexan-3-one;
- 2-[4,4-bis(4-fluorophenyl)butyl]-4-(pyridin-2-yl)methyl-2,4-diazabicyclo[3.1.0]hexan-3-one;
- 2-[4,4-bis(4-fluorophenyl)butyl]-4-benzyloxycarbonyl-2,4-
- 25 diazabicyclo[3.1.0]hexan-3-one;
- 2-[4,4-bis(4-fluorophenyl)butyl]-2,4-diaza-bicyclo[3.1.0]hexan-3-one;

and pharmaceutically acceptable salts, prodrugs and solvates thereof.

[0067] Other exemplary compounds useful in the methods of the present invention include:

1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(piperidin-1-yl)ethyl]-1,3-dihydro-benzoimidazol-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-3-yl)methyl-1,3-dihydro-benzoimidazol-2-one;

5 1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-4-yl)methyl-1,3-dihydro-benzoimidazol-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-2-yl)methyl-1,3-dihydro-benzoimidazol-2-one;

10 1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-4-yl)-1,3-dihydro-benzoimidazol-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-1,3-dihydro-benzoimidazol-2-one;

and pharmaceutically acceptable salts, prodrugs and solvates thereof.

[0068] Useful cycloalkyl groups are C₃₋₁₂ cycloalkyl. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0069] Useful halo or halogen groups include fluorine, chlorine, bromine and iodine.

[0070] Useful alkyl groups include straight-chained and branched C₁₋₁₀ alkyl groups, more preferably C₁₋₆ alkyl groups. Typical C₁₋₁₀ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, 3-pentyl, hexyl and octyl groups.

[0071] Useful haloalkyl groups include C₁₋₁₀ alkyl groups substituted by one or more fluorine, chlorine, bromine or iodine atoms (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl and trichloromethyl groups).

[0072] Useful hydroxyalkyl groups include C₁₋₁₀ alkyl groups substituted by hydroxy (e.g., hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups).

[0073] Useful aminoalkyl groups include C₁₋₁₀ alkyl groups substituted by amino (e.g., aminomethyl, aminoethyl, aminopropyl and aminobutyl groups).

[0074] Useful alkoxy groups include oxygen substituted by one of the C₁₋₁₀ alkyl groups mentioned above.

- 20 -

[0075] Useful haloalkoxy groups include oxygen substituted by one of the C₁₋₁₀ haloalkyl groups mentioned above (e.g., fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy).

[0076] The term "heterocyclic" is used herein to mean a saturated 3-7 membered monocyclic ring system having carbon atoms and from one to four heteroatoms independently selected from the group consisting of O, N, and S, wherein the nitrogen and sulfur heteroatoms can be optionally oxidized, the nitrogen can be optionally quaternized, and wherein the heterocyclic ring can be substituted on a carbon atom or on a nitrogen atom if the resulting compound is stable. Examples include, but are not limited to, aziridine, pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, pyrazolidine, oxazolidine, and the like.

[0077] Useful alkylamino and dialkylamino groups are —NHR¹⁵ and —NR¹⁵R¹⁶, wherein R¹⁵ and R¹⁶ are each independently selected from a C₁₋₁₀ alkyl group.

[0078] As used herein, the term "amino" or "amino group" refers to —NH₂.

[0079] The invention disclosed herein is also meant to encompass prodrugs of the disclosed compounds. Prodrugs are considered to be any covalently bonded carriers that release the active parent drug *in vivo*. Non-limiting examples of prodrugs include esters or amides of compounds of Formulae I-VII having hydroxyalkyl or aminoalkyl as a substituent, and these may be prepared by reacting such compounds with anhydrides such as succinic anhydride.

[0080] The invention disclosed herein is also meant to encompass the disclosed compounds being isotopically-labeled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, and ³⁶Cl, respectively. Isotopically-labeled compounds of the present invention can be prepared by methods known in the art.

[0081] The present invention is also directed specifically to ³H and ¹⁴C radiolabeled compounds of Formula I-VII, and their use as radioligands for their binding site on

the calcium channel. For example, one use of the labeled compounds of the invention is the characterization of specific receptor binding. Another use of the labeled compounds of the present invention is an alternative to animal testing for the evaluation of structure-activity relationships. The receptor assay is performed at a fixed concentration of a labeled compound of Formula I-VII and at increasing concentrations of a test compound in a competition assay. Tritiated compounds of Formula I-VII can be prepared by introducing tritium into the compound of Formula I-VII, for example, by catalytic dehalogenation with tritium. This method includes reacting a suitably halogen-substituted precursor of a compound of Formula I-VII with tritium gas in the presence of a suitable catalyst, for example, Pd/C, in the presence or absence of a base. Other suitable methods for preparing tritiated compounds can be found in Filer, *Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A)*, Chapter 6 (1987). ¹⁴C-labeled compounds can be prepared by employing starting materials having a ¹⁴C carbon.

[0082] Some of the compounds disclosed herein may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present invention is meant to encompass all such possible forms, as well as their racemic and resolved forms and mixtures thereof. The individual enantiomers may be separated according to methods known to those of ordinary skill in the art in view of the present disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are intended to be encompassed by the present invention as well.

[0083] As used herein, the term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).

[0084] The term "chiral center" refers to a carbon atom to which four different groups are attached.

[0085] The terms "enantiomer" and "enantiomeric" refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.

5 [0086] The term "racemic" refers to a mixture of equal parts of enantiomers and which mixture is optically inactive.

[0087] The term "resolution" refers to the separation or concentration or depletion of one of the two enantiomeric forms of a molecule.

[0088] The terms "a" and "an" refer to one or more.

10 [0089] The invention disclosed herein also encompasses all salts of the disclosed compounds, including all non-toxic pharmaceutically acceptable salts thereof of the disclosed compounds. Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts and basic salts. The pharmaceutically acceptable salts include, but are not limited to, metal salts such as
15 sodium salt, potassium salt, cesium salt and the like; alkaline earth metals such as calcium salt, magnesium salt and the like; organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, phosphate, sulphate and the like;
20 organic acid salts such as citrate, lactate, tartrate, maleate, fumarate, mandelate, acetate, dichloroacetate, trifluoroacetate, oxalate, formate and the like; sulfonates such as methanesulfonate, benzenesulfonate, p-toluenesulfonate and the like; and amino acid salts such as arginate, asparinate, glutamate and the like.

[0090] Acid addition salts can be formed by mixing a solution of the particular
25 compound of the present invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid, oxalic acid, dichloroacetic acid, and the like. Basic salts can be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically

acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate and the like.

[0091] The invention disclosed herein is also meant to encompass solvates of the disclosed compounds. One type of solvate is a hydrate. Solvates do not contribute significantly to the physiological activity or toxicity of the compounds and as such can function as pharmacological equivalents.

[0092] Since compounds of Formula I-VII are blockers of calcium (Ca^{2+}) channels, a number of diseases and conditions mediated by calcium ion influx can be treated by employing these compounds. Therefore, the present invention provides a method of treating, preventing or ameliorating stroke, head trauma, epilepsy, pain (e.g., acute pain or chronic pain, which includes, but is not limited to, neuropathic pain and inflammatory pain), migraine, a mood disorder, schizophrenia, a neurodegenerative disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), or Parkinson's disease), depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia. In each instance, such methods of treatment, prevention, or amelioration require administering to an animal in need of such treatment, prevention or amelioration an effective amount of a calcium channel blocking compound of the present invention, or a pharmaceutically acceptable salt, prodrug or solvate thereof.

[0093] Chronic pain includes, but is not limited to, inflammatory pain, postoperative pain, cancer pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic and postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, burn pain, and other forms of neuralgia, neuropathic, and idiopathic pain syndromes. In each instance, the methods of the present invention require administering to an animal in need of such treatment an effective amount of a calcium channel blocking compound of the present invention, or a pharmaceutically acceptable salt, prodrug or solvate thereof.

[0094] Chronic somatic pain generally results from inflammatory responses to tissue injury such as nerve entrapment, surgical procedures, cancer or arthritis (Brower,

Nature Biotechnology 2000; 18: 387-391). Although many types of inflammatory pain are currently treated with NSAIDs, there is much room for improved therapies.

[0095] The inflammatory process is a complex series of biochemical and cellular events activated in response to tissue injury or the presence of foreign substances (Levine, *Inflammatory Pain, In: Textbook of Pain*, Wall and Melzack eds., 3rd ed., 1994). Inflammation often occurs at the site of injured tissue, or foreign material, and contributes to the process of tissue repair and healing. The cardinal signs of inflammation include erythema (redness), heat, edema (swelling), pain and loss of function (ibid.). The majority of patients with inflammatory pain do not experience pain continually, but rather experience enhanced pain when the inflamed site is moved or touched. Inflammatory pain includes, but is not limited to, osteoarthritis and rheumatoid arthritis.

[0096] Chronic neuropathic pain is a heterogenous disease state with an unclear etiology. In chronic neuropathic pain, the pain can be mediated by multiple mechanisms. This type of pain generally arises from injury to the peripheral or central nervous tissue. The syndromes include pain associated with spinal cord injury, multiple sclerosis, post-herpetic neuralgia, trigeminal neuralgia, phantom pain, causalgia, and reflex sympathetic dystrophy and lower back pain. The chronic pain is different from acute pain in that patients suffer the abnormal pain sensations that can be described as spontaneous pain, continuous superficial burning and/or deep aching pain. The pain can be evoked by heat-, cold-, and mechano-hyperalgesia or by heat-, cold-, or mechano-allodynia.

[0097] Neuropathic pain can be caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to, pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Stroke (spinal or brain) and spinal cord injury can also induce neuropathic pain. Cancer-related neuropathic pain results from tumor growth compression of adjacent nerves, brain, or spinal cord. In addition, cancer

treatments, including chemotherapy and radiation therapy, can also cause nerve injury. Neuropathic pain includes but is not limited to pain caused by nerve injury such as, for example, the pain from which diabetics suffer.

[0098] The present invention is also directed to a method for treating a disorder responsive to the blockade of calcium channels, and particularly the selective blockade of N-type calcium channels, in an animal suffering from said disorder, said method comprising administering to the animal an effective amount of a compound represented by any of defined Formulae I-VII.

[0099] The present invention is also directed to the use of a compound represented by any of defined Formulae I-VII for the manufacture of a medicament, in particular a medicament for treating a disorder responsive to the blockade of calcium channels, and particularly the selective blockade of N-type calcium channels, in an animal suffering from said disorder.

[0100] Furthermore, the present invention is directed to a method of modulating calcium channels, especially N-type calcium channels, in an animal in need thereof, said method comprising administering to the animal at least one compound represented by any of defined Formulae I-VII.


[0101] The present invention is also directed to the use of a compound represented by any of defined Formulae I-VII for the manufacture of a medicament, in particular a medicament for modulating calcium channels, especially N-type calcium channels, in an animal in need thereof.

Synthesis of Compounds

[0102] The compounds of the present invention may be prepared using methods known to those skilled in the art in view of this disclosure. For example, compounds of Formula I where Z is Z¹ and R¹ and R² are both hydrogen can be prepared as shown in Schemes 1-3.

- 26 -

Scheme 1




5

[0103] Imidazolidin-2-one derivatives of Formula I where Z is Z¹ and R¹ and R² are both hydrogen can be prepared as illustrated by exemplary reactions in Scheme 2 using the methods of 1) Chern, Jyh-Haur *et al.* (*Bioorganic & Medicinal Chemistry Letters* 14(20):5051-5056 (2004)) and 2) Shia, Kak-Shan *et al.* (*Journal of Medicinal Chemistry* 45(8):1644-1655 (2002)) as shown in Scheme 2.

10

- 27 -


Scheme 2



- 5 [0104] Imidazolidin-2-one derivatives of Formula I where Z is Z¹ and R¹ and R² are both hydrogen can also be prepared as illustrated by exemplary reactions in Scheme 3 using the methods of 1) Solomon, V. Raja *et al.* (*Bioorganic & Medicinal Chemistry* 13(6):2157-2165 (2005)), 2) Donati, Donato *et al.* (*Synthesis* 16:2518-2524 (2003)), and 3) Llopart, Carme Cantos *et al.* (*Canadian Journal of Chemistry* 82(11):1649-1661 (2004)) as shown in Scheme 3.
- 10


- 28 -

Scheme 3



- 5 [0105] Compounds of Formula I where Z is Z^1 and R^1 and R^2 together with the carbon atoms to which they are attached form a fused cyclopropyl ring can be prepared as shown in Scheme 4:

Scheme 4




5

[0106] Compounds of Formula I where Z is Z¹ and R¹ and R² together with the carbon atoms to which they are attached form a fused phenyl ring can be prepared as shown in Scheme 5:

10

- 30 -

Scheme 5



5

[0107] Compounds of Formula I where Z is Z² can be synthesized using methods similar to those described in Schemes 1-5 above.

Testing of Compounds

- 10 [0108] Compounds of the present invention were assessed by calcium mobilization and/or electrophysiological assays for calcium channel blocker activity. One aspect of the present invention is the discovery that the compounds herein described are selective N-type calcium channel blockers. Based upon this discovery, these compounds are considered useful in treating, preventing, or ameliorating migraine,
- 15 epilepsy, a mood disorder, schizophrenia, a neurodegenerative disorder (such as, e.g., Alzheimer's disease, ALS, or Parkinson's disease), a psychosis, depression, anxiety,

hypertension, or cardiac arrhythmia. The compounds of the present invention are also considered to be effective in treating, preventing or ameliorating pain, such as acute pain, chronic pain, which includes, but is not limited to, neuropathic pain and inflammatory pain, or surgical pain.

5 [0109] More specifically, the present invention is directed to compounds of Formulae I-VII that are blockers of calcium channels. According to the present invention, those compounds having preferred N-type calcium channel blocking properties exhibit an IC_{50} of about 100 μM or less in the calcium mobilization and/or electrophysiological assays described herein. Preferably, the compounds of the present invention exhibit an IC_{50} of 10 μM or less. More preferably, the compounds of the present invention exhibit an IC_{50} of about 6 μM or less. Even more preferably, the compounds of the present invention exhibit an IC_{50} of about 4 μM or less. Even more preferably, the compounds of the present invention exhibit an IC_{50} of about 2 μM or less. Even more preferably, the compounds of the present invention exhibit an IC_{50} of about 1,5 μM or less. Still more preferably, the compounds of the present invention exhibit an IC_{50} of about 1.0 μM or less. Most preferably, the compounds of the present invention exhibit an IC_{50} of about 0,7 μM or less.

[0110] Compounds of the present invention can be tested for their N-type and L-type Ca^{2+} channel blocking activity by the following calcium mobilization and/or electrophysiological assays.

[0111] In one embodiment, compounds useful in the present invention are those represented by any one of Formulae I-VII that exhibit selectivity for N-type calcium channels over L-type calcium channels in the calcium mobilization and/or electrophysiological assays described herein. The phrase "selectivity for N-type calcium channels over L-type calcium channels" is used herein to mean that the ratio of an IC_{50} for L-type channel blocking activity for a compound of the present invention over an IC_{50} for N-type channel blocking activity for the same compound is more than 1, *i.e.*, $LTCC IC_{50} / NTCC IC_{50} > 1$. Preferably, compounds of the present invention exhibit an $LTCC IC_{50} / NTCC IC_{50}$ ratio of about 2 or more. More preferably, compounds of the present invention exhibit an $LTCC IC_{50} / NTCC IC_{50}$

ratio of about 4 or more. More preferably, compounds of the present invention exhibit an LTCC IC₅₀ / NTCC IC₅₀ ratio of about 6 or more. More preferably, compounds of the present invention exhibit an LTCC IC₅₀ / NTCC IC₅₀ ratio of about 9 or more. More preferably, compounds of the present invention exhibit an
5 LTCC IC₅₀ / NTCC IC₅₀ ratio of about 15 or more. More preferably, compounds of the present invention exhibit an LTCC IC₅₀ / NTCC IC₅₀ ratio of about 30 or more. More preferably, compounds of the present invention exhibit an LTCC IC₅₀ / NTCC IC₅₀ ratio of about 60 or more. Advantageously, compounds of the present invention exhibit an LTCC IC₅₀ / NTCC IC₅₀ ratio of about 100 or more.

10 ***Calcium Mobilization and Electrophysiological Assay Protocols:***

[0112] *Cell maintenance and differentiation.* Unless noted otherwise, cell culture reagents were purchased from Life Technologies of Rockville, MD. IMR32 cells (American Type Culture Collection, ATCC, Manassas, VA) were routinely cultured in growth medium consisting of minimum essential medium containing 10% fetal
15 bovine serum (FBS, Hyclone, Logan, UT), 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x MEM non-essential amino acids. 80-90 % confluent flasks of cells were differentiated using the following differentiation medium: Growth medium plus 1 mM dibutyryl cyclic AMP (Sigma, St. Louis, MO), and 2.5 µM bromodeoxyuridine (Sigma). Cells were
20 differentiated for 8 days by replacing differentiation medium every 2-3 days.

[0113] A7r5 (ATCC) cells were maintained and routinely cultured in A7r5 growth medium consisting of Dulbecco's Modified Eagles Medium containing 10 % FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 4 mM L-glutamine, and 0.15% sodium bicarbonate. 80-90 % confluent flasks of cells were differentiated using the
25 following differentiation medium: A7r5 Growth Medium plus 1 mM dibutyryl cyclic AMP (Sigma). Cells were differentiated for 8 days by replacing differentiation medium every 2-3 days.

[0114] *FLIPR Calcium Mobilization Assay for N-type Calcium Channel.* One day prior to performing this assay, differentiated IMR32 cells were treated with 1x

- 33 -

CellStripper, and seeded on poly-D-lysine-coated 96-well clear-bottom black plates (Becton Dickinson, Franklin Lakes, NJ) at 200,000 cells/well. On the day of the assay, the cell plates were washed with IMR32 buffer (127 mM NaCl, 1 mM KCl, 2 mM MgCl₂, 700 μM NaH₂PO₄, 5 mM CaCl₂, 5 mM NaHCO₃, 8 mM HEPES, 10 mM glucose, pH 7.4), then pre-stimulated with KCl and loaded as follows: 0.05 mL of IMR32 buffer, 0.05 mL of each compound tested diluted in IMR32 buffer containing 20 μM nitrendipine (Sigma), and 0.1 mL KCl dissolved in IMR32 buffer, plus Fluo-4 were added (3 μM final concentration, Molecular Probes, Eugene, OR). Final test compound concentrations ranged from about 846 pM to about 17 μM, final nitrendipine concentration was 5 μM, and final KCl concentration was 90 mM. After 1 hour, the cells were washed twice with 0.05 mL of each compound tested in nitrendipine-containing IMR32 buffer (no KCl or Fluo-4), and then replaced with 0.1 mL of each compound tested in nitrendipine-containing IMR32 buffer. Plates were then transferred to a Fluorimetric Imaging Plate Reader (FLIPR⁹⁶, Molecular Devices, Inc., Sunnyvale, CA) for assay. The FLIPR measured basal Fluo-4 fluorescence for 315 seconds (i.e., 5 minutes and 15 seconds), then added 0.1 mL KCl agonist dissolved in IMR32 buffer and measured fluorescence for another 45 seconds. Final test compound concentrations on the cells after FLIPR read ranged from about 846 pM to about 17 μM, final nitrendipine concentration was 5 μM, and final KCl concentration was 90 mM. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism (version 3.02, Graph Pad, San Diego, CA), or Activity Base (version 5.1, IDBS, Parsippany, NJ) software.

[0115] *FLIPR Calcium Mobilization Assay for L-type Calcium Channel.* One day prior to performing this assay, differentiated A7r5 cells were trypsinized, then seeded on tissue culture treated 96-well clear-bottom black plates (Becton Dickinson, Franklin Lakes, NJ) at a dilution of 1:1 from a confluent T150 cm² flask. On the day of the assay, the plates were washed with A7r5 wash buffer (127 mM NaCl, 2 mM MgCl₂, 700 μM NaH₂PO₄, 5 mM CaCl₂, 5 mM NaHCO₃, 8 mM HEPES, 10 mM glucose, pH 7.4), then loaded with 0.1 mL of A7r5 wash buffer containing Fluo-4 (3 μM final concentration, Molecular Probes, Eugene, OR). After 1 hour, the cells were

- 34 -

washed with 0.1 mL A7r5 wash buffer and resuspended in 0.05 mL A7r5 assay buffer that was composed of A7r5 wash buffer plus 50 μ M valinomycin (Sigma). Plates were then transferred to a FLIPR⁹⁶ for assay. The FLIPR measured basal Fluo-4 fluorescence for 15 seconds, then added 0.05 mL of each compound tested diluted in A7r5 assay buffer at final concentrations ranging from about 846 pM to about 17 μ M. Fluo-4 fluorescence was then measured for 5 minutes. 0.1 mL KCl agonist dissolved in A7r5 assay buffer was then added to the cells to produce a final concentration of 90 mM KCl, and fluorescence was measured for another 45 seconds. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or Activity Base software.

[0116] *Cloning of N- and L-type calcium channel subunit open reading frame cDNAs.* Five cDNAs encoding subunits of the rat N- or L-type calcium channels were cloned by PCR amplification in order to reconstitute functional channels in a heterologous system. These were the alpha1b (α 1b), beta1 (β 1), beta3 (β 3), alpha2delta (α 2 δ), and alpha1c (α 1c) subunit cDNAs. The alpha1b subunit cDNA has been described by Dubel *et al.* in *Proc. Natl. Acad. Sci. U.S.A* 89: 5058-5062 (1992). The beta1 subunit cDNA has been described by Pragnell *et al.* in *FEBS Lett.* 291: 253-258 (1991). The beta3 subunit cDNA has been described by Castellano *et al.* in *J. Biol. Chem.* 268: 12359-12366 (1993). The alpha2delta subunit cDNA has been described by Kim *et al.* in *Proc. Natl. Acad. Sci. U.S.A.* 89: 3251-3255 (1992). The alpha1c subunit cDNA has been described by Koch *et al.* in *J. Biol. Chem.* 265: 17786-17791 (1990).

[0117] The 7.0 kb cDNA containing the entire α 1b open reading frame (ORF) was PCR amplified as two overlapping cDNA fragments, i.e., a 2.7 kb 5' fragment and a 4.4 kb 3' fragment. The 5' fragment was amplified from rat brain cDNA using primers 1 (SEQ ID NO:1, TABLE 1) and 2 (SEQ ID NO:2, TABLE 1), and the 3' fragment was amplified from rat spinal cord cDNA using primers 3 (SEQ ID NO:3, TABLE 1) and 4 (SEQ ID NO:4, TABLE 1). The two fragments were joined by ligation at a common restriction site to create the entire 7.0 kb cDNA. This ORF

encodes the protein isoform generated by alternative splicing termed "+A Δ SFMG Δ ET" according to the nomenclature of Lin *et al.* (*Neuron* 18: 153-166 (1997)). The entire cDNA was sequenced with redundant coverage on both strands. The cDNA was then inserted into the mammalian expression vector pcDNA6.2DEST (Invitrogen, Carlsbad CA) by homologous recombination using the Gateway system (Invitrogen).

[0118] The 1.8 kb cDNA encoding the β 1 subunit, the 1.45 cDNA encoding the beta3 subunit, and the 3.3 kb cDNA encoding the alpha2delta subunit were cloned by PCR amplification from rat spinal cord cDNA (β 1) or brain cDNA (β 3, α 2 δ). Primers 5 (SEQ ID NO:5, TABLE 1) and 6 (SEQ ID NO:6, TABLE 1) were used for the β 1 cDNA amplification; primers 7 (SEQ ID NO:7, TABLE 1) and 8 (SEQ ID NO:8, TABLE 1) were used for the β 3 cDNA amplification; and primers 9 (SEQ ID NO:9, TABLE 1) and 10 (SEQ ID NO:10, TABLE 1) were used for the α 2 δ cDNA amplification. PCR products were subcloned and fully sequenced on both strands. Clones matching the reference sequence (β 1: NM_017346; β 3: NM_012828; α 2 δ : M86621) and the gene's GenBank rat genomic DNA sequences were recombined into the mammalian expression vector pcDNA3.2DEST (β 1, β 3) or pcDNA3.1-Zeo (α 2 δ), which had been modified to a vector compatible with the Gateway recombination system using the Gateway vector adaptor kit (Invitrogen). Proper recombination was confirmed by sequencing of recombinogenic regions. For β 3 expression vector, proper protein expression was confirmed by Western blot analysis of lysates of transfected HEK293 cells using a rabbit polyclonal antiserum directed against the rat β 3 subunit (USA Biological).

[0119] The 6.5 kb cDNA encoding the L-type calcium channel α 1c subunit was cloned by PCR amplification from rat heart cDNA using primers 11 (SEQ ID NO:11, TABLE 1) and 12 (SEQ ID NO:12, TABLE 1). The PCR fragment was subcloned and fully sequenced on both strands to confirm its identity. A clone matching consensus reference sequence M59786 and rat genomic DNA sequences was recombined into the mammalian expression vector pcDNA6.2DEST. Sequences

around the recombinogenic region were sequenced to confirm accurate recombination into the expression vector.

TABLE 1

PRIMER SEQUENCE	SEQ ID NO.
CACC ATG GTC CGC TTC GGG GAC	1
CCG TTC AGT GGC CTC CTC C	2
C TAG CAC CAG TGA TCC TGG TCTG	3
AGT GCG TTG TGA GCG CAG TA	4
CAC CAT GGT CCA GAA GAG CGG	5
TCTCAGCGGATGTAGACGCCT	6
CAC CAT GTA TGA CGA CTC CTA C	7
GGT GGT CAG TAG CTG TCC TTA GG	8
CAC CAT GGC TGC TGG CTG CCT	9
AGA GGG TCA CCA TAG ATA GTG TCT G	10
CACCATGATTCGGGCCTTCGCT	11
AGCCTGCGGACTACAGGTTGCTGAC	12

5

[0120] *N-type Recombinant Cell Line Development.* N-type calcium channel expressing HEK-293 cells were created in two stages. Stage 1 was created as follows. The rat $\alpha 1b$, and $\beta 3$ cDNA expression constructs (2.5 μ g each) were co-transfected into human embryonic kidney (HEK-293) cells by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 μ g/mL blasticidin and 500 μ g/mL geneticin, and incubated for 3 weeks at 37 °C, 5 % CO₂, 95 % humidity. Plates containing ≤ 1 clone per well were cultured until wells positive for single clones were confluent. Individual clones were then arrayed into columns of a destination 96-well plate, and partly split into 6-well plates for culture maintenance. Array plates were washed once with IMR32 buffer and cells loaded

10

15

- 37 -

for 1 hour with 0.1 mL of IMR32 buffer containing Fluo-4 (3 μ M final concentration, Molecular Probes). Then they were washed twice with 0.1 mL of IMR32 buffer, and replaced with 0.1 mL IMR32 buffer. Plates were then transferred to a FLIPR⁹⁶ for assay. The FLIPR measured basal Fluo-4 fluorescence for 315
5 seconds, then added 0.1 mL KCl agonist dissolved in IMR32 buffer and measured fluorescence for another 45 seconds. Final KCl concentration was 90 mM. Data were collected over the entire time course and analyzed using Excel, Graph Pad Prism, or Activity Base software. The clone with the greatest signal-to-noise ratio, best stability of response with passage number, and best adhesion to PDL precoated
10 plates (Becton Dickinson) was expanded, characterized and used for stage 2 cell line development.

[0121] Stage 2 of N-type cell line development was carried out as follows. The rat α 2 δ cDNA expression construct (5 μ g each) was transfected into the stage 1 N-type clonal cell line by Lipofectamine Plus reagent (Invitrogen), as per manufacturer's
15 instructions. 24 hours later, cells were split in limiting dilution into multiple 96-well plates in selection media containing 20 μ g/mL blasticidin, 500 μ g/mL geneticin, and 250 μ g/mL zeocin and incubated for 3 weeks at 37°C, 5% CO₂, 95% humidity. Plates containing \leq 1 clone per well were cultured and handled according to the same steps and procedures described above for the stage 1 cell line. The three clones with
20 the greatest signal-to-noise, best stability of response with passage number, and best adhesion to PDL precoated plates (Becton Dickinson) were expanded, characterized and tested in electrophysiology for the best current size, N-type pharmacology, N-type characteristic current-voltage relationship and kinetics as described below.

[0122] *N-type Electrophysiology in Recombinant Cells.* For electrophysiological
25 recording, the cells expressing α 1b, β 3 and α 2 δ subunits were seeded on 35-mm culture Petri dishes at a density of approximately 10⁴ cells/dish and kept in an incubator for up to three days for subsequent recordings. For recordings, the dishes were positioned on the stage of an inverted microscope (Nikon, Eclipse E600, Japan) and superfused with a bath solution comprised of BaCl₂ (11 mM), MgCl₂ (1.5 mM),

- 38 -

HEPES (10 mM), TEA chloride (120 mM), glucose (10 mM) adjusted to pH 7.4 with KOH. Whole-cell voltage-clamp recordings were made using conventional patch-clamp techniques (Hamill *et al.*, *Pfluegers Arch.* 391: 85-100 (1981)) at room temperature (22-24 °C). The patch-clamp pipettes were pulled from WPI, thick-walled borosilicate glass (WPI, Sarasota, FL). Currents were recorded using an
5 Axopatch 200A amplifier (Axon Instruments, Union City, CA) and were leak-subtracted (P/4), low-pass filtered (1 kHz, 4-pole Bessel), digitized (20-50- μ s intervals), and stored using Digidata 1200 B interface and Pclamp8.0/Clampex software (Axon Instruments, Union City, CA). The pipettes were back-filled with
10 internal solution containing CsCl (110 mM), MgCl₂ (3 mM), EGTA (3 mM), HEPES (40 mM), Mg-ATP (4 mM), Na₂GTP (0.5 mM), and adjusted to pH 7.2 with CsOH. The pipette resistance ranged from 2 to 3 MOhm and was compensated by 75-80 % by the built-in electronic circuitry.

[0123] Currents were elicited by stepping from a holding potential of -90 mV to 0
15 mV for 20 ms every 20 sec. At the -90 mV membrane voltage about 50% of channels were in the inactivated state, and thus contact with a blocker would involve interaction with both resting and inactivated channels. Every drug was applied at 3 to 4 concentrations increasing in a cumulative manner. Fractional inhibition levels in steady-state were used to draw the partial inhibition concentration curves to get the
20 IC₅₀ (i.e. concentration causing 50% reduction in the size of the response) values at -90 mV.

[0124] Stock solutions of each test compound were prepared using DMSO. Serial dilutions to desired concentrations were done with bath solution; concentration of DMSO in final solutions was 0.1 %. Drugs were applied by gravity flow using a
25 plane multi-barrel array shooter positioned 0.5 mm apart from the cell.

[0125] All curve fittings were carried out using Origin software (version 5.0, Microcal). A Hill equation was fit to the concentration-inhibition curves to determine IC₅₀ values.

[0126] *N-type Electrophysiology in Neuronal Cells.* To determine dissociation
30 constants in resting versus inactivated state for N-type calcium channels, neuronal

cells that endogenously express N-type calcium channels can be used. For electrophysiological recording, the neuronal cells expressing N-type calcium channels are seeded on 35-mm culture Petri dishes at a density of approximately 10^4 cells/dish and kept in an incubator for up to three days for subsequent recordings.

5 For recordings, the dishes are positioned on the stage of an inverted microscope (Nikon, Eclipse E600, Japan) and superfused with a bath solution comprised of BaCl_2 (11 mM), MgCl_2 (1.5 mM), HEPES (10 mM), TEA chloride (120 mM), glucose (10 mM) adjusted to pH 7.4 with KOH. Whole-cell voltage-clamp recordings are made using conventional patch-clamp techniques (Hamill *et al.*, *Pfluegers Arch.* 391:

10 85-100 (1981)) at room temperature (22-24 °C). The patch-clamp pipettes are pulled from WPI, thick-walled borosilicate glass (WPI, Sarasota, FL). Currents are recorded using an Axopatch 200A amplifier (Axon Instruments, Union City, CA) and leak-subtracted (P/4), low-pass filtered (1 kHz, 4-pole Bessel), digitized (20-50- μs intervals), and stored using Digidata 1200 B interface and Pclamp8.0/Clampex

15 software (Axon Instruments, Union City, CA). The pipettes are back-filled with internal solution containing CsCl (110 mM), MgCl_2 (3 mM), EGTA (3 mM), HEPES (40 mM), Mg-ATP (4 mM), Na_2GTP (0.5 mM), and adjusted to pH 7.2 with CsOH. The pipette resistance ranges from 2 to 3 M Ω and is compensated by 75-80 % by the built-in electronic circuitry.

20 **[0127]** Currents are elicited by stepping from a holding potential of -90 mV to 0 mV for 20 ms every 10 sec. At the -90 mV membrane voltage a proportion of channels is in the inactivated state, and thus contact with a blocker would involve interaction with both resting and inactivated channels. This protocol is used as a first tier screen. For dissection of two components of inhibition (resting block with the apparent

25 dissociation constant K_r and inactivated state block with K_i), steady-state inactivation curves are collected using a double-pulse protocol. Three-second long depolarizing pre-pulse incrementing in 10 mV steps is followed by a 10 ms test pulse to 0 mV.

[0128] Stock solutions of each test compound are prepared using DMSO. Serial dilutions to desired concentrations are done with bath solution; concentration of

- 40 -

DMSO in final solutions is 0.1 %. Drugs are applied by gravity flow using a plane multi-barrel array shooter positioned ~1 mm apart from the cell.

[0129] All curve fittings can be carried out using Origin software (version 5.0, Microcal). A Hill equation is used to fit the concentration-response curves and to determine IC₅₀ values. A Boltzman equation is used to fit inactivation curves, returning half-inactivation voltage, V_{0.5}, slope p and the amplitude of current at the most negative voltage where eventually all channels are in the resting state. These parameters are used to calculate the apparent dissociation constants: $K_r = ((Ab/Ac)/(1-(Ab/Ac))*[b])$ where [b] is the drug concentration, Ac is the maximum test current amplitude in control conditions and Ab is the maximum test current amplitude in the presence of a blocker; $K_i = [b]/((\exp(-(dx/p))*(1+([b]/K_r)) - 1)$ where dx is the difference between half-inactivation voltage V_{0.5} in the presence and absence of drug and p is the slope.

In vivo Pharmacology

[0130] The compounds of the present invention can be tested for *in vivo* anticonvulsant activity after i.v., p.o., or i.p. injection using any of a number of anticonvulsant tests in mice, including the maximum electroshock seizure test (MES). Maximum electroshock seizures are induced in male NSA mice weighing between 15-20 g and in male Sprague-Dawley rats weighing between 200-225 g by application of current (for mice: 50 mA, 60 pulses/sec, 0.8 msec pulse width, 1 sec duration, D.C.; for rats: 99 mA, 125 pulses/sec, 0.8 msec pulse width, 2 sec duration, D.C.) using a Ugo Basile ECT device (Model 7801). Mice are restrained by gripping the loose skin on their dorsal surface and saline-coated corneal electrodes are held lightly against the two corneae. Rats are allowed free movement on the bench top and ear-clip electrodes are used. Current is applied and animals are observed for a period of up to 30 seconds for the occurrence of a tonic hindlimb extensor response. A tonic seizure is defined as a hindlimb extension in excess of 90 degrees from the plane of the body. Results can be treated in a quantal manner.

[0131] The compounds can be tested for their antinociceptive activity in the formalin model as described in Hunskaar, S., O. B. Fasmer, and K. Hole, *J. Neurosci. Methods* 14: 69-76 (1985). Male Swiss Webster NIH mice (20-30 g; Harlan, San Diego, CA) can be used in all experiments. Food is withdrawn on the day of experiment. Mice are placed in Plexiglass jars for at least 1 hour to acclimate to the environment. Following the acclimation period mice are weighed and given either the compound of interest administered i.p. or p.o., or the appropriate volume of vehicle (10 % Tween-80) as control. Fifteen minutes after the i.p. dosing, and 30 minutes after the p.o. dosing mice are injected with formalin (20 μ L of 5% formaldehyde solution in saline) into the dorsal surface of the right hind paw. Mice are transferred to the Plexiglass jars and monitored for the amount of time spent licking or biting the injected paw. Periods of licking and biting are recorded in 5-minute intervals for 1 hour after the formalin injection. All experiments are done in a blinded manner during the light cycle. The early phase of the formalin response is measured as licking / biting between 0-5 minutes, and the late phase is measured from 15-50 minutes. Differences between vehicle and drug treated groups can be analyzed by one-way analysis of variance (ANOVA). A P value <0.05 is considered significant. Compounds are considered to be efficacious for treating acute and chronic pain if they have activity in blocking both the early and second phase of formalin-induced paw-licking activity.

[0132] Compounds can be tested for their potential to treat chronic pain (i.e., antiallodynic and antihyperalgesic activities) using the Chung model of peripheral neuropathy (Kim and Chung, *Pain* 50: 355-363 (1992)). Male Sprague-Dawley rats weighing between 200-225 g are anesthetized with halothane (1-3 % in a mixture of 70 % air and 30 % oxygen), and their body temperature controlled during anesthesia through use of a homeothermic blanket. A 2-cm dorsal midline incision is then made at the L5 and L6 level, and the para-vertebral muscle groups retracted bilaterally. L5 and L6 spinal nerves are then exposed, isolated, and tightly ligated with 6-0 or 7-0 silk suture. A sham operation is performed exposing the contralateral L5 and L6 spinal nerves, without ligating, as a negative control.

- 42 -

[0133] *Tactile Allodynia*: Sensitivity to non-noxious mechanical stimuli can be measured in animals to assess tactile allodynia. Rats are transferred to an elevated testing cage with a wire mesh floor and allowed to acclimate for five to ten minutes. A series of von Frey monofilaments are applied to the plantar surface of the hindpaw to determine the animal's withdrawal threshold. The first filament used possesses a buckling weight of 9.1 gms (.96 log value) and is applied up to five times to see if it elicits a withdrawal response. If the animal has a withdrawal response, then the next lightest filament in the series would be applied up to five times to determine if it also could elicit a response. This procedure is repeated with subsequent lesser filaments until there is no response and the identity of the lightest filament that elicits a response is recorded. If the animal does not have a withdrawal response from the initial 9.1 gms filament, then subsequent filaments of increased weight are applied until a filament elicits a response and the identity of this filament is recorded. For each animal, three measurements are made at every time point to produce an average withdrawal threshold determination. Tests can be performed prior to, and at 1, 2, 4 and 24 hours post drug administration.

[0134] *Mechanical Hyperalgesia*: Sensitivity to noxious mechanical stimuli can be measured in animals using the paw pressure test to assess mechanical hyperalgesia. In rats, hind paw withdrawal thresholds ("PWT"), measured in grams, in response to a noxious mechanical stimulus are determined using an analgesymeter (Model 7200, commercially available from Ugo Basile of Italy), as described in Stein (*Biochemistry & Behavior* 31: 451-455 (1988)). The rat's paw is placed on a small platform, and weight is applied in a graded manner up to a maximum of 250 grams. The endpoint is taken as the weight at which the paw is completely withdrawn. PWT is determined once for each rat at each time point. PWT can be measured only in the injured paw, or in both the injured and non-injured paw. In one non-limiting embodiment, mechanical hyperalgesia associated with nerve injury induced pain (neuropathic pain) can be assessed in rats. Rats are tested prior to surgery to determine a baseline, or normal, PWT. Rats are tested again 2 to 3 weeks post-surgery, prior to, and at different times after (e.g. 1, 3, 5 and 24 hr) drug

administration. An increase in PWT following drug administration indicates that the test compound reduces mechanical hyperalgesia.

Pharmaceutical Compositions

5 [0135] Although a compound of the present invention may be administered to a mammal in the form of a raw chemical without any other components present, the compound is preferably administered as part of a pharmaceutical composition containing the compound combined with a suitable pharmaceutically acceptable carrier. Such a carrier can be selected from pharmaceutically acceptable excipients and auxiliaries.

10 [0136] Compositions within the scope of the present invention include all compositions where a compound of the present invention is combined with a pharmaceutically acceptable carrier. In a preferred embodiment, the compound is present in the composition in an amount that is effective to achieve its intended therapeutic purpose. While individual needs may vary, a determination of optimal
15 ranges of effective amounts of each compound is within the skill of the art. Typically, the compounds may be administered to mammal, e.g. human, orally at a dose of from about 0.0025 to about 1500 mg per kg body weight of the mammal, or an equivalent amount of a pharmaceutically acceptable salt thereof, per day to treat the particular disorder. A useful oral dose of a compound of the present invention
20 administered to a mammal is from about 0.0025 to about 50 mg per kg body weight of the mammal, or an equivalent amount of the pharmaceutically acceptable salt thereof. For intramuscular injection, the dose is typically about one-half of the oral dose.

[0137] A unit oral dose may comprise from about 0.01 to about 50 mg, and
25 preferably about 0.1 to about 10 mg, of the compound. The unit dose can be administered one or more times daily as one or more tablets, each containing from about 0.01 to about 50 mg of the compound, or an equivalent amount of a pharmaceutically acceptable salt or solvate thereof.

[0138] In one embodiment, a pharmaceutical composition of the present invention can be administered orally and is formulated into tablets, dragees, capsules or an oral liquid preparation.

5 [0139] Alternatively, a pharmaceutical composition of the present invention can be administered rectally, and is formulated in suppositories.

[0140] Alternatively, a pharmaceutical composition of the present invention can be administered by injection.

[0141] Alternatively, a pharmaceutical composition of the present invention can be administered transdermally.

10 [0142] Alternatively, a pharmaceutical composition of the present invention can be administered by inhalation or by intranasal administration.

[0143] Alternatively, a pharmaceutical composition of the present invention can be administered by the intravaginal route.

15 [0144] A pharmaceutical composition of the present invention can contain from about 0.01 to 99 percent by weight, and preferably from about 0.25 to 75 percent by weight, of active compound(s).

20 [0145] The present methods of the invention, such as the method for treating, preventing, or ameliorating a disorder responsive to the blockade of calcium channels in an animal in need thereof, can further comprise administering another therapeutic agent to the animal being administered a cyclourea compound of Formula I. In one embodiment, the other therapeutic agent is administered in an effective amount.

25 [0146] Effective amounts of the other therapeutic agents are known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective-amount range. In one embodiment of the invention, where another therapeutic agent is administered to an animal, the effective amount of the compound of the present invention is less than its effective amount would be where the other therapeutic agent is not administered. In this case, without being bound by theory, it is believed that compounds of the present invention and the

other therapeutic agent act synergistically to treat, prevent, or ameliorate a disorder or condition.

[0147] The other therapeutic agent can be, but is not limited to, an opioid agonist, a non-opioid analgesic, a non-steroidal anti-inflammatory agent, an antimigraine agent, a Cox-II inhibitor, a β -adrenergic blocker, an anticonvulsant, an antidepressant, an anticancer agent, an agent for treating addictive disorder, an agent for treating Parkinson's disease and parkinsonism, an agent for treating anxiety, an agent for treating epilepsy, an agent for treating a seizure, an agent for treating a stroke, an agent for treating a pruritic condition, an agent for treating psychosis, an agent for treating ALS, an agent for treating a cognitive disorder, an agent for treating a migraine, an agent for treating vomiting, an agent for treating dyskinesia, or an agent for treating depression, and mixtures thereof.

[0148] Examples of useful opioid agonists include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphine, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacymorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, tramadol, pharmaceutically acceptable salts thereof, and mixtures thereof.

[0149] In certain embodiments, the opioid agonist is selected from codeine, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorphine, morphine, tramadol, oxymorphone, pharmaceutically acceptable salts thereof, and mixtures thereof.

[0150] Examples of useful non-opioid analgesics include non-steroidal anti-inflammatory agents, such as aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muprofen, trioxaprofen, suprofen, aminoprofen, 5 tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acetmetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal, piroxicam, sudoxicam, isoxicam, and pharmaceutically acceptable salts thereof, and mixtures thereof. Examples of other suitable non-opioid 10 analgesics include the following, non limiting, chemical classes of analgesic, antipyretic, nonsteroidal antiinflammatory drugs: salicylic acid derivatives, including aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, and olsalazin; para aminophenol derivatives including acetaminophen and phenacetin; indole and indene acetic acids, including 15 indomethacin, sulindac, and etodolac; heteroaryl acetic acids, including tolmetin, diclofenac, and ketorolac; anthranilic acids (fenamates), including mefenamic acid, and meclofenamic acid; enolic acids, including oxicams (piroxicam, tenoxicam), and pyrazolidinediones (phenylbutazone, oxyphenthartazone); and alkanones, including nabumetone. For a more detailed description of the NSAIDs, see Paul A. Insel, 20 *Analgesic Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout*, in Goodman & Gilman's *The Pharmacological Basis of Therapeutics* 617-57 (Perry B. Molinoff and Raymond W. Ruddon eds., 9th ed 1996) and Glen R. Hanson, *Analgesic, Antipyretic and Anti Inflammatory Drugs* in Remington: *The Science and Practice of Pharmacy* Vol II 1196-1221 (A.R. Gennaro 25 ed. 19th ed. 1995) which are hereby incorporated by reference in their entirety. Suitable Cox-II inhibitors and 5-lipoxygenase inhibitors, as well as combinations thereof, are described in U.S. Patent No. 6,136,839, which is hereby incorporated by reference in its entirety. Examples of useful Cox II inhibitors include, but are not limited to, rofecoxib and celecoxib.

[0151] Examples of useful antimigraine agents include, but are not limited to, alpiropride, bromocriptine, dihydroergotamine, dolasetron, ergocornine, ergocorninine, ergocryptine, ergonovine, ergot, ergotamine, flumedroxone acetate, fonazine, ketanserine, lisuride, lomerizine, methylergonovine, methysergide, metoprolol, naratriptan, oxetorone, pizotyline, propranolol, risperidone, rizatriptan, sumatriptan, timolol, trazodone, zolmitriptan, and mixtures thereof.

[0152] Examples of useful β -adrenergic blockers include, but are not limited to, acebutolol, alprenolol, amosulablol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufuralol, bunitrolol, bupranolol, butidrine hydrochloride, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol, indenolol, labetalol, levobunolol, mepindolol, metipranolol, metoprolol, moprolol, nadolol, nadoxolol, nebivalol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol, sotalol, sulfinalol, talinolol, tertatolol, tilisolol, timolol, toliprolol, and xibenolol.

[0153] Examples of useful anticonvulsants include, but are not limited to, acetylpheneturide, albutoin, aloxidone, aminoglutethimide, 4-amino-3-hydroxybutyric acid, atrolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clonazepam, decimemide, diethadione, dimethadione, doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin, felbamate, fluoresone, gabapentin, 5-hydroxytryptophan, lamotrigine, magnesium bromide, magnesium sulfate, mephenytoin, mephobarbital, metharbital, methetoin, methsuximide, 5-methyl-5-(3-phenanthryl)-hydantoin, 3-methyl-5-phenylhydantoin, narcobarbital, nimetazepam, nitrazepam, oxcarbazepine, paramethadione, phenacemide, phenetharbital, pheneturide, phenobarbital, phensuximide, phenylmethylbarbituric acid, phenytoin, phethenylate sodium, potassium bromide, pregabalin, primidone, progabide, sodium bromide, solanum, strontium bromide, suclofenide, sulthiame, tetrantoin, tiagabine, topiramate, trimethadione, valproic acid, valpromide, vigabatrin, and zonisamide.

[0154] Examples of useful antidepressants include, but are not limited to, binedaline, caroxazone, citalopram, (S)-citalopram, dimethazan, fencamine, indalpine, indeloxazine hydrochloride, nefopam, nomifensine, oxitriptan, oxypertine, paroxetine, sertraline, thiazesim, trazodone, benmoxine, iproclozide, iproniazid, 5 isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram, maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline, amitriptylinoxide, amoxapine, butriptyline, clomipramine, demexiptiline, desipramine, dibenzepin, dimetacrine, dothiepin, doxepin, fluacizine, imipramine, imipramine N-oxide, iprindole, lofepramine, melitracen, metapramine, nortriptyline, 10 noxiptilin, opipramol, pizotyline, propizepine, protriptyline, quinupramine, tianeptine, trimipramine, adrafinil, benactyzine, bupropion, butacetin, dioxadrol, duloxetine, etoperidone, febarbamate, femoxetine, fempentadiol, fluoxetine, fluvoxamine, hematoporphyrin, hypericin, levophacetoperane, medifoxamine, milnacipran, minaprine, moclobemide, nefazodone, oxaflozane, piberaline, 15 prolintane, pyrisuccideanol, ritanserin, roxindole, rubidium chloride, sulpiride, tandospirone, thozalinone, tofenacin, toloxatone, tranylcypromine, L-tryptophan, venlafaxine, viloxazine, and zimeldine.

[0155] Examples of useful anticancer agents include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, 20 ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, bropirimine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin 25 hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin, and cisplatin.

[0156] Therapeutic agents useful for treating or preventing an addictive disorder include, but are not limited to, methadone, desipramine, amantadine, fluoxetine, buprenorphine, an opiate agonist, 3-phenoxy pyridine, or a serotonin antagonist.

[0157] Examples of useful therapeutic agents for treating or preventing Parkinson's 30 disease and parkinsonism include, but are not limited to, carbidopa/levodopa,

pergolide, bromocriptine, ropinirole, pramipexole, entacapone, tolcapone, selegiline, amantadine, and trihexyphenidyl hydrochloride.

[0158] Examples of useful therapeutic agents for treating or preventing anxiety include, but are not limited to, benzodiazepines, such as alprazolam, brotizolam, 5 chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam; non-benzodiazepine agents, such as buspirone, gepirone, ipsapirone, tiospirone, zolpicone, zolpidem, and zaleplon; tranquilizers, such as barbituates, *e.g.*, 10 amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital, and thiopental; and propanediol carbamates, such as meprobamate and tybamate.

[0159] Examples of useful therapeutic agents for treating or preventing epilepsy or seizure include, but are not limited to, carbamazepine, ethosuximide, gabapentin, 15 lamotrigine, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, benzodiazepines, gamma-vinyl GABA, acetazolamide, and felbamate.

[0160] Examples of useful therapeutic agents for treating or preventing stroke include, but are not limited to, anticoagulants such as heparin, agents that break up clots such as streptokinase or tissue plasminogen activator, agents that reduce 20 swelling such as mannitol or corticosteroids, and acetylsalicylic acid.

[0161] Examples of useful therapeutic agents for treating or preventing a pruritic condition include, but are not limited to, naltrexone; nalmefene; danazol; tricyclics such as amitriptyline, imipramine, and doxepin; antidepressants such as those given below; menthol; camphor; phenol; pramoxine; capsaicin; tar; steroids; and 25 antihistamines.

[0162] Examples of useful therapeutic agents for treating or preventing psychosis include, but are not limited to, phenothiazines such as chlorpromazine hydrochloride, mesoridazine besylate, and thioridazine hydrochloride; thioxanthenes such as chlorprothixene and thiothixene hydrochloride; clozapine; risperidone; olanzapine;

- 50 -

quetiapine; quetiapine fumarate; haloperidol; haloperidol decanoate; loxapine succinate; molindone hydrochloride; pimozide; and ziprasidone.

[0163] Examples of useful therapeutic agents for treating or preventing ALS include, but are not limited to, baclofen, neurotrophic factors, riluzole, tizanidine, benzodiazepines such as clonazepam and dantrolene.

[0164] Examples of useful therapeutic agents for treating or preventing cognitive disorders include, but are not limited to, agents for treating or preventing dementia such as tacrine; donepezil; ibuprofen; antipsychotic drugs such as thioridazine and haloperidol; and antidepressant drugs such as those given below.

[0165] Examples of useful therapeutic agents for treating or preventing a migraine include, but are not limited to, sumatriptan; methysergide; ergotamine; caffeine; and beta-blockers such as propranolol, verapamil, and divalproex.

[0166] Examples of useful therapeutic agents for treating or preventing vomiting include, but are not limited to, 5-HT₃ receptor antagonists such as ondansetron, dolasetron, granisetron, and tropisetron; dopamine receptor antagonists such as prochlorperazine, thiethylperazine, chlorpromazine, metoclopramide, and domperidone; glucocorticoids such as dexamethasone; and benzodiazepines such as lorazepam and alprazolam.

[0167] Examples of useful therapeutic agents for treating or preventing dyskinesia include, but are not limited to, reserpine and tetrabenazine.

[0168] Examples of useful therapeutic agents for treating or preventing depression include, but are not limited to, tricyclic antidepressants such as amitriptyline, amoxapine, bupropion, clomipramine, desipramine, doxepin, imipramine, maprotiline, nefazadone, nortriptyline, protriptyline, trazodone, trimipramine, and venlafaxine; selective serotonin reuptake inhibitors such as citalopram, (S)-citalopram, fluoxetine, fluvoxamine, paroxetine, and setraline; monoamine oxidase inhibitors such as isocarboxazid, pargyline, phenelzine, and tranylcypromine; and psychostimulants such as dextroamphetamine and methylphenidate.

[0169] A cyclourea compound of the present invention and the other therapeutic agent can act additively or, in one embodiment, synergistically. In one embodiment,

a compound of the present invention is administered concurrently with another therapeutic agent; for example, a composition comprising an effective amount of a compound of Formulae I-VII, and an effective amount of another therapeutic agent can be administered. Alternatively, a composition comprising an effective amount of a compound of Formulae I-VII and a different composition comprising an effective amount of another therapeutic agent can be concurrently administered. In another embodiment, an effective amount of a compound of the present invention is administered prior or subsequent to administration of an effective amount of another therapeutic agent. In this embodiment, the compound of the present invention is administered while the other therapeutic agent exerts its therapeutic effect, or the other therapeutic agent is administered while the compound of the present invention exerts its preventive or therapeutic effect for treating, ameliorating or preventing a disorder or condition.

[0170] A pharmaceutical composition of the present invention can be administered to any animal that may experience the beneficial effects of a compound of the present invention. Foremost among such animals are mammals, e.g., humans and companion animals, although the invention is not intended to be so limited.

[0171] A pharmaceutical composition of the present invention can be administered by any means that achieves its intended purpose. For example, administration can be by the parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, intranasal, rectal, intravaginal or buccal route, or by inhalation. Alternatively, or concurrently, administration can be by the oral route. The dosage administered and route of administration will vary, depending upon the circumstances of the particular subject, and taking into account such factors as age, health, and weight of the recipient, condition or disorder to be treated, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

[0172] A pharmaceutical composition of the present invention is preferably manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, extrusion, or

lyophilizing processes. Thus, pharmaceutical compositions for oral use can be obtained by combining the active compound with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.

5 [0173] Suitable excipients include fillers such as saccharides (for example, lactose, sucrose, mannitol or sorbitol), cellulose preparations, calcium phosphates (for example, tricalcium phosphate or calcium hydrogen phosphate), as well as binders such as starch paste (using, for example, maize starch, wheat starch, rice starch, or potato starch), gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose,
10 sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, one or more disintegrating agents can be added, such as the above-mentioned starches and also carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.

[0174] Auxiliaries are typically flow-regulating agents and lubricants such as, for
15 example, silica, talc, stearic acid or salts thereof (e.g., magnesium stearate or calcium stearate), and polyethylene glycol. Dragee cores are provided with suitable coatings that are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and
20 suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate can be used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.

25 [0175] Examples of other pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, or soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain a compound in the form of granules, which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and,
30 optionally, stabilizers, or in the form of extruded multiparticulates. In soft capsules,

the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils or liquid paraffin. In addition, stabilizers may be added.

5 [0176] Possible pharmaceutical preparations for rectal administration include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base. Suitable suppository bases include natural and synthetic triglycerides, and paraffin hydrocarbons, among others. It is also possible to use gelatin rectal capsules consisting of a combination of active compound with a base material such as, for example, a liquid triglyceride, polyethylene glycol, or paraffin hydrocarbon.

10 [0177] Suitable formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form such as, for example, a water-soluble salt, alkaline solution, or acidic solution. Alternatively, a suspension of the active compound may be prepared as an oily suspension. Suitable lipophilic solvents or vehicles for such as suspension may include fatty oils (for example, sesame oil),
15 synthetic fatty acid esters (for example, ethyl oleate), triglycerides, or a polyethylene glycol such as polyethylene glycol-400 (PEG-400). An aqueous suspension may contain one or more substances to increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. The suspension may optionally contain stabilizers.


20 [0178] The following examples are illustrative, but not limiting, of the compounds, compositions and methods of the present invention. Suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art in view of this disclosure are within the spirit and scope of the invention.

Examples

EXAMPLE 1

1-[4,4-Bis(4-fluorophenyl)butyl]-imidazolidin-2-one (3)

- 5 [0179] To a suspension of sodium hydride (0.72 g, 18 mmol) in DMF (20.0 mL) was added a solution of imidazolidin-2-one (1) (2.5 g, 30.0 mmol, Aldrich) in DMF (10.0 mL) at room temperature. The resulting mixture was stirred at room temperature for 45 minutes and then a solution of 4,4-bis(4-fluorophenyl)butyl chloride (2) (5.6 g, 10 mmol) in DMF (10.0 mL) was added. Then the mixture was stirred at 60 °C for 4
- 10 hours. After this period, the mixture was cooled to room temperature and quenched with water (20 mL). The mixture was extracted with ethyl acetate (100 mL x 3). The organic layer was dried with anhydrous Na₂SO₄ and concentrated to give a crude sample. The crude sample was purified by column chromatography using ethyl acetate/hexane gradient as an eluent to give the title compound 3. MS: *m/z* 331. ¹H
- 15 NMR (CDCl₃): δ 7.16 (m, 4H), 6.96 (t, J=8 Hz, 4H), 4.36 (br, 1H), 3.91 (t, J=8 Hz, 1H), 3.38 (m, 2H), 3.32 (m, 2H), 3.21 (t, J=8 Hz, 2H), 2.00 (dd, J=8, 12 Hz, 2H), 1.45 (m, 2H).




EXAMPLE 2

- 20 1-[4,4-Bis(4-fluorophenyl)butyl]-3-(pyridin-2-ylmethyl)imidazolidin-2-one (5)

[0180] To a suspension of sodium hydride (0.06 g, 1.6 mmol) in DMF (1.0 mL) was added a solution of 1-[4,4-bis(4-fluorophenyl)butyl]imidazolidin-2-one (3) (0.2 g,

- 55 -

0.6 mmol) in DMF (1.0 mL) at room temperature. The resulting mixture was stirred at 70 °C for 1.0 hour and cooled to room temperature before adding a solution of compound 4 (0.16 g, 1 mmol, Aldrich) in DMF (0.5 mL). The resulting reaction mixture was stirred at 70 °C for 4 hours. After this period, the mixture was cooled to room temperature and quenched with water (5.0 mL). The mixture was extracted with chloroform (10 mL x 2). The organic layer was dried (Na₂SO₄) and concentrated to give a crude sample. The crude sample was purified by column chromatography using ethyl acetate/hexane gradient as an eluent to give 65 mg of the title compound 5 as a clear oil. MS: *m/z* 422. ¹H NMR (400 MHz, CDCl₃): δ 8.56-8.49 (m, 1H), 7.66-7.59 (m, 1H), 7.34-7.26 (m, 2H), 7.22-7.11 (m, 4H), 7.02-6.90 (m, 4H), 4.49 (s, 2H), 3.96-3.88 (m, 1H), 3.33-3.16 (m, 6H), 2.07-1.96 (m, 2H), 1.53-1.44 (m, 2H).



[0181] The following compounds were prepared similarly:

15 [0182] 1-[4,4-Bis(4-fluorophenyl)butyl]-3-(pyridin-3-ylmethyl)imidazolidin-2-one:
¹H NMR (400 MHz, CDCl₃): δ 8.52 (m, 2H), 7.62 (m, 1H), 7.24 (m, 1H), 7.16 (dd, J=5.2, 8.3 Hz, 4H), 6.96 (m, 4H), 4.37 (s, 2H), 3.92 (t, J=7.9 Hz, 1H), 3.25 (t, J=6.9 Hz, 2H), 3.17 (m, 4H), 2.01 (m, 2H), 1.45 (m, 2H). MS: *m/z* 422.2 (M+1).

20 [0183] 1-[4,4-Bis(4-fluorophenyl)butyl]-3-(pyridin-4-ylmethyl)imidazolidin-2-one:
¹H NMR (400 MHz, CDCl₃): δ 8.54 (m, 2H), 7.17 (m, 6H), 6.97 (m, 4H), 4.36 (s, 2H), 3.93 (t, J=7.7 Hz, 1H), 3.27 (t, J=7.1 Hz, 2H), 3.20 (m, 4H), 2.02 (m, 2H), 1.45 (m, 2H). MS: *m/z* 422.2 (M+1).

[0184] 1-[4,4-Bis(4-fluorophenyl)butyl]-3-[2-(piperidin-1-yl)ethyl]-imidazolidin-2-one: ^1H NMR (400 MHz, CDCl_3): δ 7.16 (m, 4H), 6.96 (m, 4H), 3.90 (t, $J=7.9$ Hz, 1H), 3.32 (m, 4H), 3.17 (m, 4H), 2.42 (m, 6H), 1.99 (m, 2H), 1.54 (m, 4H), 1.42 (m, 4H). MS: m/z 442.4 (M+1).


5

EXAMPLE 3

2-[4,4-Bis(4-fluorophenyl)butyl]-4-benzyloxycarbonyl-2,4-diaza-bicyclo[3.1.0]hexan-3-one (8)

2-[4,4-Bis(4-fluorophenyl)butyl]-2,4-diaza-bicyclo[3.1.0]hexan-3-one (9)


10 [0185] 3-Oxo-2,4-diaza-bicyclo[3.1.0]hexane-2-carboxylic acid benzyl ester (6) (0.78 g, 3.34 mmol, Rare Chemicals GmbH) was dissolved in DMF (10.0 mL). Potassium hydroxide (0.28 g, 5.0 mmol) was added to the solution followed by compound 7 (1.37 g, 3.67 mmol). The resulting mixture was stirred at room temperature for 5 hours. Then the mixture was diluted with water (10.0 mL) and
 15 extracted with methylene chloride (50 mL x 3). The organic layer was dried with anhydrous Na_2SO_4 and concentrated to give a crude sample. The crude sample was purified by column chromatography using ethyl acetate/methylene chloride gradient as an eluent to give 1.13 g of the title compound 8 and 90 mg of the title compound 9. MS for compound 8: m/z 477. MS for compound 9: m/z 343.



EXAMPLE 4

2-[4,4-Bis(4-fluorophenyl)butyl]-4-(pyridin-2-yl)methyl-2,4-diaza-bicyclo[3.1.0]hexan-3-one (**10**)

- 5 **[0186]** 2-[4,4-Bis(4-fluorophenyl)butyl]-2,4-diaza-bicyclo[3.1.0]hexan-3-one (**9**) (90 mg, 0.263 mmol) was dissolved in DMF (3.0 mL). Sodium hydride (11 mg, 0.39 mmol) was added to the solution followed by compound **4** (48 mg, 0.26 mmol). The resulting mixture was stirred at room temperature for 15 hours. Then the mixture was diluted with water (1.0 mL) and extracted with methylene chloride (5 ml x 3).
- 10 The organic layer was dried with anhydrous Na₂SO₄ and concentrated to give a crude sample. The crude sample was purified by column chromatography using ethyl acetate/methylene chloride gradient as an eluent to give 20 mg of the title compound **10** as clear oil. MS: *m/z* 434. ¹H NMR (CDCl₃): δ 8.58-8.52 (m, 1H), 7.67-7.61 (m, 1H), 7.35-7.25 (m, 5H), 7.04-6.93 (m, 4H), 4.69-4.62 (m, 1H), 4.53-4.43 (m, 1H),
- 15 3.99-3.86 (m, 1H), 3.37-3.27 (m, 2H), 3.14-3.04 (m, 1H), 2.99-2.90 (m, 1H), 2.11-1.95 (m, 2H), 1.59-1.48 (m, 2H), 1.28-1.23 (m, 1H), 0.50-0.42 (m, 1H).




- [0187]** Similarly, 2-[4,4-bis(4-fluorophenyl)butyl]-4-methyl-2,4-diaza-bicyclo[3.1.0]hexan-3-one was prepared. ¹H NMR (CDCl₃): δ 7.16 (m, 4H), 6.96 (m, 4H), 3.91 (t, J=8 Hz, 1H), 3.24 (m, 2H), 3.00 (m, 1H), 2.92 (m, 1H), 2.85 (s, 3H), 2.01 (m, 2H), 1.52 (m, 2H), 1.25 (s, 1H), 0.45 (dd, J=5.7, 11.8 Hz, 1H). MS: *m/z* 357.1 (M+1).
- 20

- 58 -

EXAMPLE 51-[4,4-Bis(4-fluorophenyl)butyl]-1,3-dihydro-benzoimidazol-2-one (**12**)


[0188] To a suspension of sodium hydride (0.72 g, 18 mmol) in DMF (15.0 mL) was added a solution of 1,3-dihydro-benzoimidazol-2-one (**11**) (2.6 g, 20.0 mmol, Aldrich) in DMF (10.0 mL) at room temperature. The resulting mixture was stirred at room temperature for 30 minutes and a solution of compound **2** (2.8 g, 10 mmol) in DMF (10.0 mL) was added. The resulting mixture was stirred at 60 °C for 4 hours. After this period, the mixture was cooled to room temperature and quenched with water (20 mL). The mixture was extracted with ethyl acetate (100 mL x 3). The organic layer was dried with anhydrous Na₂SO₄ and concentrated to give a crude sample. The crude sample was purified by column chromatography using ethyl acetate/hexane gradient as an eluent to give the title compound **12**. MS: *m/z* 379. ¹H NMR (CDCl₃): δ 9.41 (s, 1H), 7.10 (m, 8H), 6.92 (t, J=8 Hz, 4H), 3.93 (m, 3H), 2.07 (m, 2H), 1.73 (m, 2H).

**EXAMPLE 6**1-[4,4-Bis(4-fluorophenyl)butyl]-3-(pyridin-2-yl)methyl-1,3-dihydro-benzoimidazol-2-one (**13**)

[0189] To a suspension of sodium hydride (0.06 g, 1.5 mmol) in DMF (1.0 mL) was added a solution of 1-[4,4-bis(4-fluorophenyl)butyl]-1,3-dihydro-benzoimidazol-2-one (**12**) (0.19 g, 0.5 mmol) in DMF (1.0 mL) at room temperature. The resulting

- 59 -

mixture was stirred at 70 °C for 1 hour and cooled to room temperature before adding a solution of compound **4** (0.16 g, 1 mmol, Aldrich) in DMF (0.5 mL). The resulting mixture was stirred at 70 °C for 4 hours. After this period, the mixture was cooled to room temperature and quenched with water (5.0 mL). The mixture was extracted with chloroform (10 mL x 2). The organic layer was dried (Na₂SO₄) and concentrated to give a crude sample. The crude sample was purified by column chromatography using ethyl acetate/hexane gradient as an eluent to give 65 mg of the title compound **13** as clear oil. MS: *m/z* 469. ¹H NMR (CDCl₃): δ 8.64 (s, 1H), 8.53 (s, 1H), 7.64-7.56 (m, 1H), 7.23-7.16 (m, 1H), 7.16-7.08 (m, 4H), 7.08-6.98 (m, 2H), 6.98-6.90 (m, 4H), 6.90-6.84 (m, 2H), 5.08 (s, 2H), 4.00-3.87 (m, 3H), 2.11-1.99 (m, 2H), 1.79-1.66 (m, 2H).



[0190] Similarly, the following compounds were prepared:

[0191] 1-[4,4-Bis(4-fluorophenyl)butyl]-3-[2-(piperidin-1-yl)ethyl]-1,3-dihydrobenzoimidazol-2-one: ¹H NMR (CDCl₃): δ 7.12 (dd, J=5.3, 8.8 Hz, 4H), 7.05 (m, 3H), 6.93 (m, 4H), 6.84 (m, 1H), 4.00 (dd, J=8.0, 14.4 Hz, 2H), 3.90 (m, 3H), 2.62 (m, 2H), 2.46 (m, 4H), 2.04 (dd, J=7.6, 15.0 Hz, 2H), 1.70 (m, 2H), 1.54 (m, 4H), 1.41 (m, 2H). MS: *m/z* 490.4 (M+1);

[0192] 1-[4,4-Bis(4-fluorophenyl)butyl]-3-(pyridin-3-yl)methyl-1,3-dihydrobenzoimidazol-2-one: ¹H NMR (CDCl₃): δ 8.64 (br s, 1H), 8.53 (br s, 1H), 7.60 (d, J=7.7 Hz, 1H), 7.20 (dd, J=4.9, 7.7 Hz, 1H), 7.13 (dd, J=5.3, 8.6 Hz, 4H), 7.03 (m, 2H), 6.94 (m, 4H), 6.88 (m, 2H), 5.08 (s, 2H), 3.94 (m, 3H), 2.05 (m, 2H), 1.73 (m, 2H). MS: *m/z* 470.2 (M+1);

- 60 -

[0193] 1-[4,4-Bis(4-fluorophenyl)butyl]-3-(pyridin-4-yl)methyl-1,3-dihydrobenzoimidazol-2-one: ^1H NMR (CDCl_3): δ 8.52 (br s, 2H), 7.14 (m, 6H), 7.04 (m, 2H), 6.94 (m, 5H), 6.79 (m, 1H), 5.06 (s, 2H), 3.95 (m, 3H), 2.05 (m, 2H), 1.75 (m, 2H). MS: m/z 470.1 (M+1); and

- 5 [0194] 1-[4,4-Bis(4-fluorophenyl)butyl]-3-(pyridin-4-yl)-1,3-dihydrobenzoimidazol-2-one: ^1H NMR (CDCl_3): δ 8.76 (m, 2H), 7.61 (dd, $J=1.4, 4.6$ Hz, 2H), 7.28 (m, 2H), 7.14 (m, 5H), 6.95 (m, 5H), 3.96 (t, $J=7.2$ Hz, 1H), 3.94 (m, 2H), 2.10 (m, 2H), 1.77 (m, 2H). MS: m/z 456.1 (M+1).

EXAMPLE 7

- 10 [0195] Compounds of the invention described exhibit an IC_{50} value of from about 0.34 μM to about 5 μM when tested in the calcium mobilization and/or electrophysiological assay for N-type calcium channel blocking activity. Some compounds described have been tested in the calcium mobilization assay for L-type calcium channel blocking activity and they exhibit an IC_{50} value of from about 0.20
- 15 μM to about $> 20 \mu\text{M}$. Representative values are presented in TABLE 2.

TABLE 2

Evaluation of the tested compounds as N-type calcium channel (NTCC) blockers and L-type calcium channel (LTCC) blockers after a calcium mobilization *in vitro* assay

COMPOUND	NTCC IC ₅₀ (μ M)	LTCC IC ₅₀ (μ M)
1-(3,3-diphenylpropyl)-3-phenylimidazolidin-2-one	4.33	10~20
1-[4,4-bis(4-fluorophenyl)butyl]-imidazolidin-2-one	3.69	
1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-4-ylmethyl)imidazolidin-2-one	1.19	3.43
1-[4,4-bis(4-fluorophenyl)butyl]-3-(3-phenylprop-2-enyl)imidazolidin-2-one	1.14	3.63
1-[4,4-bis(4-fluorophenyl)butyl]-3-methylimidazolidin-2-one	0.67	0.79
1-[4,4-bis(4-fluorophenyl)butyl]-3-cyclopropylimidazolidin-2-one	0.62	0.41
1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(pyrrolidin-1-yl)ethyl]imidazolidin-2-one	1.36	3.56
2-[4,4-bis(4-fluorophenyl)butyl]-4-benzyloxycarbonyl-2,4-diazabicyclo[3.1.0]hexan-3-one	0.34	3.29
1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(piperidin-1-yl)ethyl]-1,3-dihydro-benzoimidazol-2-one	2.15	> 20
1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-2-yl)methyl-1,3-dihydro-benzoimidazol-2-one	0.81	4.69

5

[0196] Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof.

- 62 -


[0197] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following
5 claims.

[0198] All patents and publications cited herein are fully incorporated by reference herein in their entirety.

- 63 -

CLAIMS


1. A compound having the Formula I:



I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:

- 5 Z is selected from the group consisting of Z¹ and Z², wherein



and

Z² is $-\text{CH}_2-(\text{CH}_2)_n-\text{R}^8$;


R¹ and R² are both hydrogen or R¹ and R², together with the carbon atoms to which they are attached, form a fused cyclopropyl ring or a fused phenyl ring;

- 10 R³ is selected from the group consisting of


- (i) hydrogen;
- (ii) alkyl;
- (iii) C₃₋₆ cycloalkyl;
- (iv) $-(\text{CH}_2)_p-\text{Y}$;

15

(v)




(vi)



5

(vii)



R^4 , R^5 , R^6 , and R^7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

R^8 is selected from the group consisting of phenyl optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

pyridyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, and alkoxy;

thiazolyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, and haloalkyl;

- 65 -

R^9 and R^{10} are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

R^{11} and R^{12} are each independently selected from the group consisting of
5 hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

wherein Y is a 3-7 membered saturated heterocyclic ring optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and
10 hydroxyalkyl;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, or 2;

p is 0, 1, 2, 3, or 4;

q and s are each independently 0, 1, 2, 3, 4, or 5;

15 r is 0 or 1;

t is 1, 2, 3, or 4; and

u is 0, 1, 2, 3, or 4;


with the provisos that

1) when R^1 and R^2 are both hydrogen, Z is Z^2 , and R^3 is (i) or (v),
20 where r is 0 and R^9 and R^{10} are each independently hydrogen or alkoxy,
then R^8 is not phenyl or 3,4-dimethoxyphenyl; or

2) when R^1 and R^2 together form a fused phenyl ring, Z is Z^2 , and R^8
is an unsubstituted phenyl group, then R^3 is not alkyl.

2. The compound of claim 1, having the


a) Formula II:



II

5 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R³ and Z are as defined in claim 1; or

b) Formula III:




III

10 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R³ and Z are as defined in claim 1; or

c) Formula IV:

- 67 -



IV


or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R^3 and Z are as defined in claim 1.

3. The compound of any one of claims 1 or 2, wherein Z is Z^1 or Z^2 .

5

4. The compound of claim 5, wherein Z is Z^1 , having

a) the Formula V:




V

10

or a pharmaceutically acceptable salt, prodrug or solvate thereof; or

- 68 -


b) the Formula VI



or a pharmaceutically acceptable salt, prodrug or solvate thereof; or

c) the Formula VII:

5



or a pharmaceutically acceptable salt, prodrug, or solvate thereof.

5. The compound of any one of claims 1-4, wherein R³ is


a) selected from the group consisting of (i) hydrogen, (ii) alkyl, and (iii) C₃₋₆ cycloalkyl; or

5

b) (iv) $-(CH_2)_p-Y$, wherein Y is a 3-7 membered saturated heterocyclic ring optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl, and p is 0, 1, 2, 3, or 4; or

10


c) (v)



wherein R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl, r is 0 or 1, and q and s are each independently 0, 1, 2, 3, 4, or 5, or

15


d) (vi)



wherein R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl, and t is 0, 1, 2, 3, or 4.

25

e) (vii)



wherein R¹¹ and R¹² are each independently selected from the group consisting of
 5 hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and
 hydroxyalkyl, and u is 0, 1, 2, 3, or 4.

6. The compound of any one of claims 1-5, wherein R⁴, R⁵, R⁶ and R⁷
 are each independently selected from the group consisting of hydrogen, alkyl,
 10 alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, cyano, amino, alkylamino, and
 dialkylamino and preferably wherein R⁴ and R⁶ are both hydrogen and R⁵ and R⁷ are
 each independently selected from the group consisting of hydrogen, alkyl, alkoxy,
 halogen, haloalkyl, haloalkoxy, hydroxy, cyano, amino, alkylamino, and
 dialkylamino.

15

7. The compound of claim 4, which is:

a) a compound according to Formula V, which is

1-(3,3-diphenylpropyl)-3-phenylimidazolidin-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-phenylimidazolidin-2-one;

20 1-[4,4-bis(4-fluorophenyl)butyl]-3-(3-phenylprop-2-enyl)imidazolidin-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-3-ylmethyl)imidazolidin-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-4-ylmethyl)imidazolidin-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-2-ylmethyl)imidazolidin-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-methylimidazolidin-2-one;

25 1-[4,4-bis(4-fluorophenyl)butyl]-3-cyclopropylimidazolidin-2-one;

1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(pyrrolidin-1-yl)ethyl]imidazolidin-2-
 one;

- 1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(piperidin-1-yl)ethyl]imidazolidin-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-imidazolidin-2-one;
- or a pharmaceutically acceptable salt, prodrug or solvate thereof, or
- 5 b) a compound according to Formula VI, which is
- 2-[4,4-bis(4-fluorophenyl)butyl]-4-methyl-2,4-diazabicyclo[3.1.0]hexan-3-one;
- 2-[4,4-bis(4-fluorophenyl)butyl]-4-(pyridin-2-yl)methyl-2,4-diazabicyclo[3.1.0]hexan-3-one;
- 10 2-[4,4-bis(4-fluorophenyl)butyl]-4-benzyloxycarbonyl-2,4-diazabicyclo[3.1.0]hexan-3-one;
- 2-[4,4-bis(4-fluorophenyl)butyl]-2,4-diaza-bicyclo[3.1.0]hexan-3-one;
- or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
- 15 c) a compound according to Formula VII, which is:
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-[2-(piperidin-1-yl)ethyl]-1,3-dihydrobenzoimidazol-2-one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-3-(pyridin-3-yl)methyl-1,3-dihydrobenzoimidazol-2-one;
- 20 1-[4-bis(4-fluorophenyl)butyl]-3-(pyridin-4-yl)methyl-1,3-dihydrobenzoimidazol-2-one;
- 1-[4-bis(4-fluorophenyl)butyl]-3-(pyridin-2-yl)methyl-1,3-dihydrobenzoimidazol-2-one;
- 1-[4-bis(4-fluorophenyl)butyl]-3-(pyridin-4-yl)-1,3-dihydrobenzoimidazol-2-
- 25 one;
- 1-[4,4-bis(4-fluorophenyl)butyl]-1,3-dihydrobenzoimidazol-2-one;
- or a pharmaceutically acceptable salt, prodrug or solvate thereof

- 72 -


8. The compound of claim 3, wherein $Z = Z^2$ and R^8 is
- a) phenyl optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkoxy, hydroxy, halogen, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino, or
 - b) pyridyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, and alkoxy; or
 - c) thiazolyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, and haloalkyl.

9. The compound of claim 1, wherein said compound has an IC_{50} of about 100 μ M or less for N-type calcium channel blocking activity in a calcium mobilization and/or electrophysiological assay.

10. A pharmaceutical composition, comprising the compound as claimed in any one of claims 1-9 and a pharmaceutically acceptable carrier.

20


11. A method of treating, preventing or ameliorating a disorder responsive to the blockade of calcium channels in a mammal suffering from excess activity of said channels, comprising administering to a mammal in need of such treatment, prevention or amelioration an effective amount of a compound of Formula I:




I

25 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:

Z is selected from the group consisting of Z¹ and Z², wherein



and




R¹ and R² are both hydrogen or R¹ and R², together with the carbon atoms to which they are attached, form a fused cyclopropyl ring or a fused phenyl ring;


R³ is selected from the group consisting of

- (i) hydrogen;
- (ii) alkyl;
- (iii) C₃₋₆ cycloalkyl;
- (iv) $-(\text{CH}_2)_p-\text{Y}$;
- (v)

10




(vi)



15

(vii)



- 74 -

R^4 , R^5 , R^6 , and R^7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

5 R^8 is selected from the group consisting of
phenyl optionally substituted with one, two or three substituents
independently selected from the group consisting of alkyl, alkoxy, halogen,
haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl,
alkylamino, and dialkylamino;

10 pyridyl optionally substituted with one or two substituents
independently selected from the group consisting of alkyl, halogen, haloalkyl,
haloalkoxy, and alkoxy;

thiazolyl optionally substituted with one or two substituents
independently selected from the group consisting of alkyl, alkoxy, halogen,
15 and haloalkyl;

R^9 and R^{10} are each independently selected from the group consisting of
hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and
hydroxyalkyl;

20 R^{11} and R^{12} are each independently selected from the group consisting of
hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and
hydroxyalkyl;

wherein Y is a 3-7 membered saturated heterocyclic ring optionally
substituted with one or two substituents independently selected from the group
consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and
25 hydroxyalkyl;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, or 2;

p is 0, 1, 2, 3, or 4;

q and s are each independently 0, 1, 2, 3, 4, or 5;

30 r is 0 or 1;

- 75 -

t is 1, 2, 3, or 4; and


u is 0, 1, 2, 3, or 4; or

as set forth in any one of claims 1-9.

12. The method of claim 11, wherein a disorder responsive to the
5 blockade of N-type calcium channels is treated, prevented or ameliorated.

13. A method of treating, preventing or ameliorating stroke, head trauma,
epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative
disorder, depression, anxiety, a psychosis, hypertension, or cardiac arrhythmia in a
mammal, comprising administering an effective amount of a compound of


10 Formula I:



I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:

Z is selected from the group consisting of Z¹ and Z², wherein



and


Z² is $-\text{CH}_2-(\text{CH}_2)_n-\text{R}^8$;

15 R¹ and R² are both hydrogen or R¹ and R², together with the carbon atoms to
which they are attached, form a fused cyclopropyl ring or a fused phenyl ring;


R³ is selected from the group consisting of

- 76 -


- (i) hydrogen;
(ii) alkyl;
(iii) C₃₋₆ cycloalkyl;
(iv) $-(CH_2)_p-Y$;
5 (v)



(vi)



(vii)



10

R^4 , R^5 , R^6 , and R^7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

15

R^8 is selected from the group consisting of

phenyl optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

20

pyridyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, and alkoxy;

- 77 -

thiazolyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, and haloalkyl;

R^9 and R^{10} are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

R^{11} and R^{12} are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

wherein Y is a 3-7 membered saturated heterocyclic ring optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, or 2;

p is 0, 1, 2, 3, or 4;

q and s are each independently 0, 1, 2, 3, 4, or 5;

r is 0 or 1;

t is 1, 2, 3, or 4; and


u is 0, 1, 2, 3, or 4; or

as set forth in any one of claims 1-9,
to a mammal in need of such treatment, prevention or amelioration.


14. The method of claim 13, wherein the method is of treating, preventing or ameliorating pain, preferably acute pain, chronic pain or surgical pain and more preferably chronic pain.

- 78 -


15. A method of modulating calcium channels, preferably N-type calcium channels, in a mammal, comprising administering to the mammal at least one compound of Formula I:



5 or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
Z is selected from the group consisting of Z¹ and Z², wherein



and




R¹ and R² are both hydrogen or R¹ and R², together with the carbon atoms to
10 which they are attached, form a fused cyclopropyl ring or a fused phenyl ring;


R³ is selected from the group consisting of

- (i) hydrogen;
- (ii) alkyl;
- (iii) C₃₋₆ cycloalkyl;
- (iv) $-(\text{CH}_2)_p-\text{Y}$;
- (v)


15



(vi)



(vii)



5

R^4 , R^5 , R^6 , and R^7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

10 R^8 is selected from the group consisting of

phenyl optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

15 pyridyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, and alkoxy;

thiazolyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, and haloalkyl;

20

- 80 -

R⁹ and R¹⁰ are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

R¹¹ and R¹² are each independently selected from the group consisting of
5 hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

wherein Y is a 3-7 membered saturated heterocyclic ring optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and
10 hydroxyalkyl;

m is 0, 1, 2, 3, 4, or 5;

n is 0, 1, or 2;

p is 0, 1, 2, 3, or 4;

q and s are each independently 0, 1, 2, 3, 4, or 5;

15 r is 0 or 1;

t is 1, 2, 3, or 4; and

u is 0, 1, 2, 3, or 4; or

as set forth in any one of claims 1-9.

20 16 A compound having the Formula I as claimed in any one of claims 1-9, wherein the compound is ³H or ¹⁴C radiolabeled.


17. A method for screening a candidate compound for the ability to bind to a receptor using a radiolabeled compound of claim 16, comprising:

25 a) introducing a fixed concentration of the radiolabeled compound to the receptor to form a mixture;

b) titrating the mixture with the candidate compound ; and


c) determining the binding of the candidate compound to said receptor.

18. Use of a compound of Formula I as claimed in any one of claims 1-9 or of a compound of Formula I:



or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:

5 Z is selected from the group consisting of Z¹ and Z², wherein




and

Z² is $-\text{CH}_2-(\text{CH}_2)_n-\text{R}^8$;


R¹ and R² are both hydrogen or R¹ and R², together with the carbon atoms to which they are attached, form a fused cyclopropyl ring or a fused phenyl ring;

10 R³ is selected from the group consisting of


- (i) hydrogen;
- (ii) alkyl;
- (iii) C₃₋₆ cycloalkyl;
- (iv) $-(\text{CH}_2)_p-\text{Y}$;
- 15 (v)



(vi)



(vii)



5

R^4 , R^5 , R^6 , and R^7 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

R^8 is selected from the group consisting of

10 phenyl optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, cyano, amino, aminoalkyl, alkylamino, and dialkylamino;

pyridyl optionally substituted with one or two substituents

15 independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, and alkoxy;

thiazolyl optionally substituted with one or two substituents

independently selected from the group consisting of alkyl, alkoxy, halogen, and haloalkyl;

20 R^9 and R^{10} are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

R^{11} and R^{12} are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, hydroxy, and

25 hydroxyalkyl;

- 83 -

wherein Y is a 3-7 membered saturated heterocyclic ring optionally substituted with one or two substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cyano, hydroxy, and hydroxyalkyl;

- 5 m is 0, 1, 2, 3, 4, or 5;
 n is 0, 1, or 2;
 p is 0, 1, 2, 3, or 4;
 q and s are each independently 0, 1, 2, 3, 4, or 5;
 r is 0 or 1;
- 10 t is 1, 2, 3, or 4; and
 u is 0, 1, 2, 3, or 4;

for the manufacture of a medicament for treating, preventing or ameliorating stroke, head trauma, epilepsy, pain, migraine, a mood disorder, schizophrenia, a neurodegenerative disorder, depression, anxiety, a psychosis, hypertension, or
15 cardiac arrhythmia in a mammal, and preferably acute pain, chronic pain, or surgical pain.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/000303

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D233/34 C07D235/02 C07D235/26 C07D401/06 A61K31/41
A61P29/00 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TAPIA I ET AL: "2,3-DIHYDRO-2-OXO-1H-BENZIMIDAZOLE-1-CARB OXAMIDES WITH SELECTIVE AFFINITY FOR THE 5-HT4 RECEPTOR: SYNTHESIS AND STRUCTURE-AFFINITY AND STRUCTURE-ACTIVITY RELATIONSHIPS OF A NEW SERIES OF PARTIAL AGONIST AND ANTAGONIST DERIVATIVES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 15, 1999, pages 2870-2880, XP002310533 ISSN: 0022-2623 use: p. 2871, left col., last paragraphcompounds 13K, 13L	1-3,5,6, 8-10,18
X	FR 1 516 714 A (BAYER AG) 5 February 1968 (1968-02-05) examples 22,25	1-3,5,6, 8-10
	----- -/--	

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

15 March 2007

Date of mailing of the international search report

29/03/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fritz, Martin

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/000303

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 268 229 A2 (TANABE SEIYAKU CO [JP]) 25 May 1988 (1988-05-25) examples 39-41,52,92-95	1-3,5,6, 8-10
X	NOMOTO Y ET AL: "STUDIES ON CARDIOTONIC AGENTS III. SYNTHESIS OF 1-U1-(6,7-DIMETHOXY-4-QUINAZOLINYL)-4- PIPERIDINYL-3-SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLIDINETHIONE DERIVATIVES" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 38, no. 9, 1 September 1990 (1990-09-01), pages 2467-2471, XP000604961 ISSN: 0009-2363 compound 31	1-3,5,6, 8-10
X	RAJU ET AL.: "Solution-Phase Parallel Synthesis of Substituted Benzimidazoles" J. COMB. CHEM., vol. 4, 2002, pages 320-328, XP002424963 compound 17D	1-3,5,6, 8-10
X	WO 97/14417 A (MERCK & CO INC [US]; ASKEW BEN C [US]; HARTMAN GEORGE D [US]; DUGGAN M) 24 April 1997 (1997-04-24) Cpd. 20-3 page 191	1-3,5,6, 8-10
X	CLARK ET AL.: "Synthesis of Some substituted Benzimidazolones" J. AM. CHEM. SOC., vol. 80, 1958, pages 1657-1662, XP002424964 7th cpd.; 20th cpd. page 1659	1-3,5,6, 8-10
X	DE 24 00 094 A1 (JANSSEN PHARMACEUTICA NV) 18 July 1974 (1974-07-18) page 39; compounds 7,8	1-3,5,6, 8-10
A	WO 2005/087747 A (SCION PHARMACEUTICALS INC; ZELLE ROBERT [US]) 22 September 2005 (2005-09-22) the whole document	1-18
P,X	WO 2006/023844 A (ENTREMED INC [US]; AGOSTON GREGORY E [US]; HEMBROUGH TODD A [US]; LAVA) 2 March 2006 (2006-03-02) p. 84, 2nd cpd. p. 85, 1st cpd.	1-3,5,6, 8-10

-/--

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/000303

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2006/136561 A (TIBOTEC PHARM LTD [IE]; BONFANTI JEAN-FRANCOIS [FR]; MULLER PHILIPPE []) 28 December 2006 (2006-12-28) Cpd. s-2 on p. 41 -----	1-3, 5, 6, 8-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2007/000303

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 11-15 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/000303

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
FR 1516714	A	05-02-1968	NONE	
EP 0268229	A2	25-05-1988	AU 597444 B2	31-05-1990
			AU 8112587 A	19-05-1988
			CA 1304376 C	30-06-1992
			CN 87107864 A	31-08-1988
			DE 3780259 D1	13-08-1992
			DE 3780259 T2	24-12-1992
			DK 597687 A	15-05-1988
			ES 2046193 T3	01-02-1994
			FI 874865 A	15-05-1988
			GR 3005227 T3	24-05-1993
			HU 45983 A2	28-09-1988
			IE 61446 B1	02-11-1994
			IL 84409 A	15-12-1991
			JP 1793079 C	14-10-1993
			JP 5000396 B	05-01-1993
			JP 63239281 A	05-10-1988
			US 4886817 A	12-12-1989
WO 9714417	A	24-04-1997	AU 713247 B2	25-11-1999
			AU 7432296 A	07-05-1997
			EP 0866705 A1	30-09-1998
			JP 11513686 T	24-11-1999
DE 2400094	A1	18-07-1974	AU 6418474 A	10-07-1975
			BE 809410 A2	04-07-1974
			FR 2213059 A1	02-08-1974
			JP 49095980 A	11-09-1974
			NL 7400132 A	08-07-1974
			US 3910930 A	07-10-1975
WO 2005087747	A	22-09-2005	AU 2005222399 A1	22-09-2005
			CA 2558214 A1	22-09-2005
			EP 1723119 A1	22-11-2006
WO 2006023844	A	02-03-2006	NONE	
WO 2006136561	A	28-12-2006	NONE	